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Chronic heart failure (CHF) is one of the most prevalent chronic diseases, affecting 
approximately 3% of the general population. It is even more frequently present in the 
elderly, with a prevalence of 10-20% in people aged above 70 years. The prevalence 
of CHF increased dramatically over the past decennia, due to a combination of 
increased ageing of the general population and increased survival due to improved 
medical care for CHF patients.1
Although treatment options for CHF have improved tremendously over the past 
decennia, it is still one of the major causes of morbidity and mortality in Western 
countries. CHF impairs quality of life2 and has a 5-year survival rate as low as ~50%, 
which is worse than for most types of cancer.3
 
TELOMERES – THE BEGINNING
In 1908 Alexis Carrel, a surgeon who was awarded with the Nobel Prize for his 
work on vascular suture and organ transplantation, became interested in growing 
cells outside of the body. Het started cell culture experiments to investigate the life 
span of cells in vitro. He succeeded in keeping cell cultures from chicken embryo 
heart alive, and after 85 days of successfully culturing these cells he published an 
article in which he concluded that cells could be kept alive for a long time, if not 
indefinitely, outside the body.4 His cell cultures seemed to really grow indefinitely, 
and that experiment was finally terminated after 34 years.5
 The concept of infinite cell growth also became attractive to other investigators. 
When Leonard Hayflick and Paul Moorhead tried to repeat these experiments, they 
came to the contrary conclusion that cells could only enter cell cycle a fixed number 
of times, before going into “senescence”, a state in which cells were not dead but 
had stopped dividing. They provided convincing evidence that withspoke the 
results and conclusions from Carrel’s experiments. Nowadays, we acknowledge that 
Hayflick and Moorhead were right about the concept of limited cell division. This 
phenomenon is now widely known as the Hayflick limit.6 Intriguingly, the truth 
behind the experiments of Alexis Carrel has never been revealed. Some scientists 
speculate that is it probable that the cell cultures were kept alive by the accidental or 
deliberate addition of fresh cells to the cultures daily.7,8
 The investigations in cell cycle and the limiting factor in this process 
continued. One could say that the discovery of telomeres followed inevitably. In 
1978, the first report of telomeres was made by Elizabeth Blackburn in the protozoan 
Tetrahymena.9 Telomeres are the distal ends of chromosomes. They consist of 
repeats of nucleotide sequences. Due to erosion, the ‘wear and tear’ of our DNA, 
and incomplete DNA replication after every cell cycle telomeres shorten throughout 
lifetime. When telomeres become critically short, cells will eventually become 
senescent or dysfunctional.10 Therefore, it is not surprising that short telomere 
length has been associated with organ dysfunction and disease. 
TELOMERES AND CHF
Telomere length has been associated with cardiovascular disease and risk factors. 
Most evidence has been gathered on the association between short telomere 
length and atherosclerotic disease.11-14 More recently, telomeres have also been 
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demonstrated to be associated with CHF, in both mouse models and patients.
 Life style choices and other environmental factors can influence telomere 
length negatively.15-17 However, telomere length has also shown to be largely 
determined by parental telomere length.18,19 This gives rise to the intriguing question 
whether inherited short telomeres could be a factor in people that contributes to 
the (familial) predisposition for atherosclerotic disease and chronic heart failure, 
independently from life style choices.
AIMS OF THIS THESIS
Despite the clinical observations on the association between telomere length and 
CHF, the precise mechanism – if there is one - behind this association is still unclear. 
In addition, the evidence of a causal relationship between short telomeres and CHF 
is lacking. This thesis aimed at further exploring the associations between telomere 
length and CHF and risk factors. Subsequently, a mechanistical explanation for 
these associations has been sought. 
The first part of this thesis focuses on the clinical associations between telomere 
length and CHF and risk factors. Chapter 1 provides an overview of the associations 
between telomere and chronic heart failure and associated factors. Chapter 2 and 3 
describe the associations between anaemia and renal dysfunction – both frequent 
co-morbidities of CHF –and short telomere length. Chapter 4 reports a longitudinal 
study aimed at assessing associations between telomere length trajectory and 
risk factors for CHF. To date, only few longitudinal studies have been performed 
investigating the associations between telomere length and cardiovascular risk 
factors in time.  
 The second part of this thesis focuses on providing a possible mechanistical 
explanation for the relationship between heart failure and short telomere length. 
Chapter 5 describes a premature ageing mouse model and the use of this model 
in exploring the underlying mechanisms linking telomere shortening and 
cardiovascular disease. In Chapter 6, telomere length in cardiovascular progenitor 
cells – one of the possible underlying mechanisms linking telomere shortening 
and cardiovascular dysfunction - has been investigated in ischaemic heart failure 
patients, healthy controls, and their offspring. Chapter 7 summarises the recent 
discoveries on the role of telomere length in cardiovascular disease and discusses 
future perspectives in telomere length in the field of cardiovascular research. 
Chapter 8 is a summary of the other chapters of this thesis and discusses some 
fututre perspective of the role of telomere length in cardiovascular research and 
practice.
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The incidence and prevalence of cardiovascular disease increases progressively with 
advancing age. Cardiovascular disease is a major cause of morbidity and mortality 
in Western Countries. In the near future, as the population ages, it is expected that 
the population prevalence of cardiovascular disease will increase dramatically, 
imposing a major social and economical burden on society. Not only is age closely 
related to the development and progression of cardiovascular disease, but genetic 
and environmental factors also play an important role. Recently, a chromosomal 
mechanism, telomere shortening, has been considered a driving force by which 
genetic and environmental factors jointly affect biological ageing, and possibly 
the risk for developing age-associated diseases. Telomeres are the extreme ends 
of chromosomes and shorten progressively during every cell cycle and therefore 
can be considered an indicator of biological age. In heart failure, telomere length 
is severely reduced. In the current review, we will discuss the emerging role of 
telomere biology in the pathophysiology of heart failure.
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INTRODUCTION
The incidence of cardiovascular disease, including atherosclerosis and chronic 
heart failure, increases progressively with advancing age.1 Cardiovascular disease 
represents one of the major causes of morbidity and mortality in Western Countries. 
In the near future, as the population ages, it is expected that the prevalence of 
patients with cardiovascular diseases will increase dramatically, imposing a major 
social and economical burden on society. Although medical and interventional 
therapies have greatly improved event free survival, the prognosis of chronic heart 
failure (CHF) remains poor2-4 and the search for new strategies to improve outcome 
continues.5 Many patients with disorders associated with cardiovascular ageing 
also have concomitant chronic disorders of other organ systems, including those of 
the kidneys and lungs. 
 Not only are age and concomitant diseases strongly related to the development 
and progression of CHF, but genetic and environmental factors also play important 
roles. Only recently, have telomeres been considered as a driving force by which 
genetic and environmental factors jointly affect biological age and pace of ageing, 
and consequently the risk of developing disorders related to ageing.6 
 In vitro, most somatic cells can undergo only a finite number of cell divisions 
before reaching senescence. This phenomenon was discovered in the sixties by the 
famous experiments of Leonard Hayflick.7 This so-called “Hayflick limit” originates 
from progressive shortening of telomeres during each cell division. Therefore, 
telomeres are considered indicators or markers of biological age. The potential role 
of telomeres and telomerase in the development and progression of cardiovascular 
diseases is only just beginning to be recognised.6
 In the current review, we discuss the potential role of telomeres and telomere 
maintenance in chronic heart failure and risk factors.
TELOMERES AND TELOMERASE
Structure and function
Chromosomal integrity is required for an organism to function and survive.8 
Several mechanisms contribute to chromosomal integrity. One essential mechanism 
is chromosomal capping by telomeres. However, the exact function and regulation 
of chromosomal capping by telomeres are only just beginning to be understood.9,10 
Telomeres are specialised functional deoxyribonucleic acid (DNA)–protein 
complexes which are located at both extreme ends of each chromosome. Telomeres 
are arranged in such a way that they can form loop structures (T- and D-loops), 
that act as a protective chromosomal “cap” (figure 1). The telomere sequence varies 
among species. In humans telomeres are composed of arrays of (TTAGGG)n up 
to 20 kilo-base pairs in length, terminating in a 3’ single stranded DNA overhang 
consisting of 100–400 nucleotides.11,12
 The chromosomal caps formed by telomeres prevent the loss of genetic 
information and prevent the chromosomes from being recognised as double 
stranded DNA breaks by DNA damage signalling mechanisms. Telomere capping 
also prevents the detrimental end-to-end fusion and chromosomal degradation, 
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which leads to cellular senescence or even apoptosis.9,10
 Using quantitative fluorescence in situ hybridization techniques, the length of 
telomeres on specific chromosomes has been studied. In humans, women tend to 
have longer telomeres than men. This difference has been attributed to potential 
telomerase upregulation by oestrogens.13 For all chromosomes there is a linear 
correlation between length and age.14 It has been suggested that the telomere 
length of chromosome 17p is shorter than the median telomere length.15 However, 
13p and 19p also have been identified as having the shortest telomeres.14,16 In 
women, accelerated shortening of telomeres has been documented in the inactive 
X chromosome.17 In males, there does not seem to be a difference in attrition rate 
between the Y and X chromosomes.14 Nevertheless, it remains to be determined 
whether low average telomere length or specific chromosome arms are responsible 
for inducing senescence.
 Unfortunately, telomeres are unstable structures. In each cell the holoenzyme 
DNA polymerase aims to replicate telomeres, just like any other chromosomal 
regions. The regular DNA polymerases fail to completely replicate the human 
telomeric DNA, a difficulty referred to as the “end-replication problem”. Up to a 
few hundred base pairs of telomeric DNA are lost during each mammalian mitosis. 
This erosion of telomere length is a cumulative process and eventually the telomere 
will progress into a critical short, dysfunctional one, leading to cellular senescence 
or even apoptosis.10,18-20 Since telomeres mark the number of cell divisions, they 
are regarded as a biological counter, and as such a marker of biological age.18,21-24 
However, telomere length per se is only one of the many variables which determine 
the potential of telomeres to form a protective structure.8
 In contrast to chronological age, defined by date of birth, it may be possible 
to modify or influence biological ageing. Indeed, species as a whole are not ageing 
leading to extinction, but instead are reproducing for many millions of years. 
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Figure 1. Simplified depiction of a telomere folded in T-loop formation. Telomeres consist 
of specific nucleotide repeats (TTAGGG and AATCCC) at both ends of each chromosome.
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achieved by several mechanisms, including by the specialised ribonucleoprotein 
enzyme telomerase, which can add the specific TTAGGG repeats to the 
chromosomal ends.25 Under physiological conditions, in humans, telomerase is 
only active in embryogenic stem cells, germline cells and some epithelial and 
lymphoid progenitor cells.26,27 Human telomerase is composed of two essential 
protein components, human TElomerase Reverse Transcriptase (hTERT), and an 
RNA component, the human Telomerase RNA Component (hTRC).28 Increased 
activity of telomerase has been linked to immortalisation of cells, uncontrollable 
growth and even malignancies.18 Decreased activity of telomerase and extremely 
short telomeres have been linked to dyskeratosis congenita, a congenital, multi-
system disorder, phenotypically characterized by mucocutaneous abnormalities, 
pulmonary aberrations, premature ageing, and early death due to bone marrow 
insufficiency.29,30  Both the X-linked and autosomal dominant form of dyskeratosis 
congenita are associated with defects of telomerase and short telomeres. This 
strongly suggests that telomerase activity is required to maintain telomere length. 
In addition, short telomeres and absence of telomerase have been shown to result in 
premature ageing in humans.29,30
Telomere repeat binding factors and telomere function
Telomeres are unable to form the protective T- and D-loops without the assistance of 
several essential proteins. The single most important are the mammalian Telomere 
Repeat binding Factors (TRF) 1 and TRF2. TRF1 and TRF2 can bind directly to 
the telomeric DNA region and facilitate the formation of the protective loops 
(figure 1). In the absence of TRFs, telomeres lose these protective loop structures. 
Telomere length itself is an important determinant of the ability to form protective 
loops. However, in the presence of sufficiently high levels of TRF2, even short 
telomeres can form protective loop structures.9 Nevertheless, an abundance of 
TRF2 proteins has also been related to increased telomere shortening in vitro.9,31 Too 
much TRF2 seems to lead to compromised repair of oxidative telomeric damage, 
although it does not affect repair of genomic DNA.31 A satisfactory explanation for 
these apparently contrary effects of TRF2 has yet to be provided.
Figure 2. Relationships between telomeres and cellular processes, cardiovascular disease, 




Oxidative stress and telomere length
In addition to telomerase dysfunction, several other processes are associated with 
increased telomere attrition rate and short telomeres. Oxidative stress, independent 
of its origin, is considered the major cause of telomere erosion.32 Cultured vascular 
smooth muscle cells and endothelial cells exposed to oxidative stress, exhibit 
increased shortening of telomeres and accelerated cellular senescence.33  In addition, 
telomerase activity decreases in response to oxidative stress, which is thought to 
be a direct consequence of oxidative stress, rather than the result of premature 
senescence.34 Smoking and obesity are well-known factors causing in vivo oxidative 
stress, and are both linked to decreased telomere length.35 Alternatively, strategies to 
reduce oxidative stress (e.g. a state of hypoxia or by overexpression of anti-oxidant 
enzymes) can maintain telomere length and have been associated with increased 
telomerase activity.36,37
TELOMERES, TELOMERASE AND FACTORS LEADING TO CHRONIC HEART 
FAILURE
CHF is a complex, multi-causal, polygenic disorder of different aetiologies which 
is becoming increasingly prevalent as the population ages.38,39 Hypertension, 
diabetes, and smoking are well-known risk factors for the progression of coronary 
artery disease and the development of CHF (figure 2), but have also been related to 
reduced telomere length. We will discuss risk factors for CHF and their relationship 
with telomere dynamics below.
Hypertension
Hypertension, leading to left ventricular hypertrophy and diastolic dysfunction, 
is an important early factor involved in the development of CHF. In addition to 
diastolic dysfunction, it leads to systolic dysfunction and ventricular dilatation.40,41
 Hypertension has been shown to be associated with reduced telomere length 
in several, but not all, studies.42-44 In hypertensive men, white blood cell (WBC) 
telomere length has been shown to be shorter compared to normotensive men, 
even after adjustment for chronological age.43 In patients with type 1 diabetes, 
hypertensive subjects had shorter telomeres than non-hypertensive, but this 
difference failed to reach significance after additional adjustment for age.44 Pulse 
pressure, the difference between diastolic and systolic blood pressure, which 
is known to increase with age, is regarded as an indicator of biological ageing of 
central arteries45, and predicts cardiovascular mortality.46 In men, telomere length in 
white blood cells (WBCs) negatively correlates with pulse pressure, independently 
from age.21,45 The relationship between telomere length and pulse pressure in 
women is inconsistent.21,45 The renin-angiotensin system is associated with outcome 
in patients with coronary heart disease.47 Interestingly, in the Framingham Heart 
Study, shorter telomere length was also related to higher renin-to-aldosterone 
ratio, especially in participants with hypertension.48 Interestingly, telomerase 
knockout mice with reduced telomere length also suffer from hypertension due 
to an increased expression of the endothelin-converting enzyme and consequently 
increased serum levels of the vasoconstrictor peptide endothelin-1.49 
21
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Diabetes mellitus
Diabetes mellitus is another important risk factor for the development of 
atherosclerosis and CHF. Diabetes can lead to cardiac dysfunction through 
several complementary mechanisms. Increased levels of non-esterified fatty acids 
in diabetes alter the activity of K-channels at the myocyte membrane, leading to 
decreased cardiac contractility.50 In addition, the heart is less affected by insulin 
resistance compared to other organs. As insulin acts as a growth factor, stimulating 
cell growth through nuclear transcription pathways, hyperinsulinaemia can 
induce cardiac hypertrophy.51 Furthermore, hyperglycaemia in diabetes results 
in increased production of deleterious advanced glycation end products (AGEs), 
which negatively affect cardiac contractility and ventricular filling pressures.51 
 Diabetes is also associated with reduced telomere length. Type 1 diabetes 
mellitus patients have shorter telomeres in WBCs compared to non-diabetic 
controls.44 Potential confounders such as age, duration of diabetes, or albuminuria 
showed no independent correlation with telomere length. Type 2 diabetes mellitus 
has also been associated with shorter telomeres compared to healthy age- and 
sexmatched controls.52 There may also be a difference between monocyte and 
lymphocyte telomere length. Monocyte telomere length has been demonstrated to 
be significantly shorter in type 2 diabetic patients, but no difference was observed 
for lymphocyte telomere length.53 The reason for the differential expression of 
telomere length among subpopulations of peripheral WBCs is unclear. Interestingly, 
insulin resistance has also been reported to be associated with reduced telomere 
length.43,54
Cigarette smoking
Cigarette smoking is widely known to be related to the development of coronary 
heart disease (CHD)55 and consequently the development of CHF. Smoking 
predisposes to several other atherosclerotic syndromes, including intermittent 
claudication, cerebrovascular disease, and glomerular sclerosis. Smoking decreases 
nitric oxide bioavailability and subsequently vasomotor function, and increases 
inflammation, leukocyte adhesion, and platelet activation.55 Smoking slightly 
increases the number of circulating leukocytes, thereby possibly promoting 
systemic inflammation. 
 Smoking has also repeatedly been associated with reduced telomere length. 
In women, the mean telomere length of WBCs is shorter in smokers than in non-
smokers in a dose-dependent manner.35 Furthermore, a dose-dependent negative 
relationship between pack years and telomere length in peripheral lymphocytes 
was found in both patients with chronic obstructive pulmonary disease and controls 
with normal lung function.56 Also, among bladder cancer patients and controls, 
telomere length of WBCs was gradually decreased with increasing number of pack 
years smoked.57 However, not all studies have consistently observed a negative 





In addition to the association between telomeres and the risk factors for 
atherosclerosis, a relationship between telomeres and atherosclerotic disease 
itself has also been observed.23,59-62 WBC telomere length in patients who had 
a myocardial infarction before the age of 50 years was shorter than in healthy 
controls, independently from other atherosclerotic risk factors.23 These findings 
have been confirmed in other cohorts of patients with coronary disease.59,62 Not only 
are WBC telomeres shorter, but telomeres of coronary artery endothelial cells of 
atherosclerotic plaques are also shorter compared to non-atherosclerotic segments 
and healthy controls.60
 Telomere length also predicts future coronary heart disease. In a study, 
involving 383 subjects, shorter WBC telomere length was associated with an 
approximately three times higher risk of myocardial infarction.23 This finding was 
recently confirmed in a larger study involving 1542 subjects, which demonstrated 
that subjects with a WBC telomere length of the lowest or middle tertile were at 
increased risk of developing CHD compared to individuals with the longest 
telomeres.63 In addition, the absolute benefit of pravastatin treatment was greatest 
in patients with the shortest telomeres.63
 Whether short telomeres are causally involved in the pathogenesis of 
hypertension, diabetes, or atherosclerosis requires further evaluation. The 
alternative explanation, that telomere length marks the cumulative life burden of 
leukocyte turnover or inflammation, cannot be denied.
Valvular heart disease
Valvular heart diseases, such as aortic valve stenosis, can also lead to the 
development of CHF due to prolonged increased cardiac strain, which causes left 
ventricle hypertrophy and eventually dilatation and compromised cardiac pump 
function. Aortic valve abnormalities can be congenital or degenerative, and age-
related.64 Recently, degenerative aortic stenosis has also been associated with 
decreased leukocyte telomere length independently from possible confounding 
factors. This may be due to a telomere-dependent decrease in regenerative capacity 
associated with ageing.64
Iatrogenic
Many anti-cancer drugs cause cardiotoxicity or introduce a risk of delayed 
cardiovascular events. Although direct effects on cardiomyocytes are likely, 
chemotherapy also induces permanent telomere shortening in blood and bone 
marrow and possibly in other cells.65 Currently, several new strategies in the 
oncology field are aimed at inhibiting telomerase to slow down cell proliferation. 
Monitoring of the patients included in studies of these new strategies for 
cardiovascular side effects, is therefore important.
TELOMERES, TELOMERASE, AND CHRONIC HEART FAILURE
CHF is characterised by increased myocyte apoptosis.66,67 Several studies in 
animal models have provided important pathophysiological insights into the role 
23
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of telomeres and telomerase in cardiac failure and myocyte apoptosis.67-70 Later 
generations of telomerase knockout (Terc−/−) mice show progressively shortened 
telomeres. Telomere shortening in these mice is associated with attenuated myocyte 
proliferation, increased apoptosis and cardiac myocyte hypertrophy. Eventually, left 
ventricular failure and pathological cardiac remodelling, mimicking the end stage 
dilated cardiomyopathy of humans, develops in these mice with critically short 
telomeres.69 In vitro experiments with cultured rat myocytes have demonstrated 
that downregulation of TRF2 leads to telomere attrition, activation of the pro-
apoptotic protein Chk2, and eventually apoptosis. Conversely, upregulation of 
TRF2 can protect myocytes from premature apoptosis.67 Mechanical myocyte stress, 
comparable to cardiac strain in hypertension, also shortens telomeres and induces 
Chk2 related apoptosis. In this in vitro model, forced hTERT expression could 
reverse telomere attrition and related apoptosis.67
 Recently, it has been suggested that cardiac cells are not simply a homogenous 
population of post-mitotic cells. Instead, the myocardium consists of a heterogeneous 
population of myocytes from different biological age categories, myocytes appear 
to age prematurely under pathophysiological conditions. Experiments in mice have 
demonstrated that the heart is constantly repopulating the myocyte compartment 
to replace old, functionally impaired myocytes with younger ones.71 The old, 
senescent, poorly contracting myocytes were found to have severely shortened 
telomeres, while the young and more efficient cells had longer telomeres.71 A 
possible source of myocytes for repopulation of the myocardium could be the pool 
of cardiac progenitor cells (CPCs). It has been reported that CPCs have stem cell 
like potential, increase in number after myocardial infarction72, and can migrate to 
damaged regions of the myocardium and generate young myocytes.73 In human 
failing hearts, telomeres are shorter compared to healthy, age-matched controls. 
This suggests that telomere shortening in the heart does not necessarily accompany 
normal ageing. A possible explanation for the increased number of dysfunctional, 
prematurely aged myocytes could be the shortened telomeres observed in failing 
hearts.
 In animals with forced TERT expression, telomerase activity is increased. 
This prevents telomere erosion and results in increased myocyte density, either 
by hyperplasia or decreased apoptosis.70 Myocytes with forced TERT expression 
also exhibit increased incorporation of mitosis markers compared to control in the 
first weeks after birth. This suggests a delay of cell cycle exit, and thus replicative 
abilities of myocytes, under the influence of telomerase activity.70 Another 
histological hallmark of heart failure is a decreased capillary density.74 Endothelial 
progenitor cells are an important source of vascular repair and maintenance.75 Short 
telomeres significantly reduce the angiogenic potential of progenitor cells.76 Over-
expression of TERT, resulting in an increase of telomerase activity and maintenance 
of telomere length, prolongs the life span and proliferation potential of cultured 
vascular smooth muscle cells.36
 As mentioned previously, atherosclerosis — a risk factor for heart failure 
— is associated with shorter telomeres. However, recent studies in humans have 
also suggested an important role for telomeres in the pathophysiology of non-
ischaemic CHF. Endomyocardial biopsies from 19 elderly patients with dilated 
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cardiomyopathy were compared with biopsies from 7 subjects of comparable age 
but without cardiomyopathy. Myocytes from the aged diseased hearts showed 
significant telomeric shortening, cellular senescence, and cell death.66 Using 
confocal microscopy, a 39% reduction in average telomere length in CHF patients 
compared to healthy controls was observed.66 These preliminary findings were 
recently substantiated in a large cohort of 620 CHF patients compared to 183 age- 
and sexmatched controls (figure 3).62 Telomeres were shown to be related to the 
severity of heart failure as they were shorter in patients with higher New York Heart 
Association (NYHA) class. Ischaemic aetiology was an additional factor associated 
with shorter telomeres in patients with CHF. Even the number of atherosclerotic 
manifestations was associated with shorter telomeres (table 1).62 In patients with 
CHF, telomere length was shorter in those with renal dysfunction than in those 
without.77 There are suggestions that telomere length is associated with reduced 
ejection fraction in the elderly (table 1).78 
 Notwithstanding all these promising associations, we have to be careful when 
drawing conclusions regarding cause or effect. The exact mechanism explaining the 
relationship between reduced telomere length and CHF remains to be elucidated. 
Although data from experimental models strongly suggests a causal role, evidence 
beyond associations in humans is now required. The major limitation of almost all 
human data is its cross-sectional nature, or the lack of telomere length follow-up.
Interestingly, not much is known about telomere length in specific subpopulations 
of circulating WBCs. Most researchers have determined telomere length in easily 
accessible circulating WBCs. However, these might not be the most relevant cells to 
consider in CHF.
THERAPEUTIC OPPORTUNITIES
If short telomeres and decreased telomerase activity indeed play a role in 
pathogenesis of cardiovascular disease, this provides opportunities for intervention. 
Telomere length in easily obtainable WBCs might provide an early marker of 
increased cardiovascular risk and could therefore be used to identify patients 
who would benefit most from early primary preventive treatment strategies.23,42,63 
For example, TRF2 in endothelial progenitor cells can be increased by statin 
therapy in vitro.79 These statin treated EPCs also have lower levels of Chk2.79 
Telomere modifying strategies might be useful in stem cell transplantation or for 
intracoronary infusion of cells after myocardial infarction. Gene therapy is another 
conceivable approach. For example, specific over-expression of telomerase or TRF2 
could contribute to the stability of telomeres, which in turn could contribute to 
better function of cells directly involved in angiogenesis. Forced hTERT expression 
in mice has been shown to lead to ventricular hypertrophy without compromising 
ventricular function and increased tolerance to ischaemia.70 However, as we 
discussed earlier, increased telomerase activity can also lead to immortalisation 
of cells, which could possibly result in the growth of malignancies. As with all 
treatments, the balance between therapeutic benefit and harmful side effects must 
be found.
 Besides pharmacological and gene therapy, behavioural changes could also 
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reduce telomere attrition rate. Smoking cessation and increased physical activity 
also have potential as effective interventions, and may be exceptionally effective in 
patients with short telomeres.
Table 1. Literature overview of the relationship between telomeres and heart failure
Study subjects Main findings Ref.
Suggestive for causal relationship between telomeres and heart failure
Dogs TERT upregulation, indicating increased telomerase activity, was 
found shortly after induced heart failure. Possibly, telomerase activity 
increases in newly developed heart failure to preserve telomere length 





Counteracting telomere shortening by TERT overexpression has ben-
eficial effects on cardiac morphology, decreases infarct size in vivo, and 
rescues myocytes from apoptosis after hypoxia in vivo and in vitro.
78
Mice Ablation of telomerase, and subsequently short telomeres, lead to 
myocyte apoptosis, decreased cardiomyocyte number, abnormal 
myocardial fibre morphology, decreased cardiac myocyte proliferation, 
myocyte hypertrophy, decreased +dP/dt, decreased –dP/dt, decreased 
LV developed pressure, elevated LV end-diastolic pressure, develop-
ment dilated cardiomyopathy, left ventricular failure, and death due to 
heart failure.
77
Mice Cardiac strain induces telomere shortening and myocyte apoptosis in 
the myocardium. Over-expression of TERT has cardioprotective effects. 
75
Rats Functionally competent cardiac progenitor cells, which are thought to 
be able to regenerate damaged or aged myocardium, had longer telo-
meres than the aged cardiac progenitor cells.
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Human,
myocardium
Shorter telomere length was measured in myocardium of hearts with 




Myocytes from hearts diseased from ageing cardiomyopathy had ap-




In chronic ischemic heart failure myocardial telomerase activity was 
increased compared to normal hearts, but less increased than in hearts 
with acute myocardial infarction. In chronic ischemic heart failure 
more cardiac progenitor cells with short telomere length were found 




Severity of heart failure, expressed in NYHA class, is correlated to 
shorter telomere length. Telomere length was shorter in case of ischae-





Ventricular ejection fraction was correlated to shorter telomere length 





Telomere length and telomerase have recently been shown to be associated with 
cardiovascular disease and its risk factors. Critically short telomeres, changes 
in telomere-binding proteins, and decreased telomerase activity have all been 
implicated in the activation of cellular damage pathways, and eventually cellular 
dysfunction, senescence and apoptosis. It remains to be elucidated whether WBC 
telomere shortening, which is frequently observed in CHD and CHF is a cause or 
a consequence of the disease. Future experimental and epidemiological studies 
to determine telomere length in relation to cardiac function will contribute to our 
understanding of the role of telomeres in cardiovascular disease and might open up 
new avenues for risk stratification and interventions.
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Anaemia is associated with shorter 
leukocyte telomere length in patients 




Anaemia is highly prevalent and associated with poor prognosis in patients 
with chronic heart failure (CHF). Reduced erythroid proliferation capacity of 
haematopoietic progenitor cells is associated with reduced telomere length, a 
marker of cellular ageing. We hypothesize that short telomere length contributes to 
the susceptibility to develop anaemia in patients with CHF.
 We studied 875 CHF patients, of whom 254 (29%) fulfilled the WHO criteria of 
anaemia. Telomere length in DNA from peripheral leukocytes was measured with 
real-time quantitative polymerase chain reaction.
 Age, gender, and baseline differences adjusted telomere length was correlated 
with haemoglobin levels (partial r=.130; P =0.011). One standard deviation shorter 
telomere length was associated with an increased risk of having anaemia [odds 
ratio (OR), 1.31; 95% confidence interval (CI), 1.12–1.53; P=0.001]. This observation 
was not affected by adjustment for potential confounders (OR, 1.38; 95% CI, 1.05–
1.81; P = 0.021 after adjustment for age, gender, erythropoietin levels, renal function, 
left ventricular ejection fraction, age of CHF onset, blood pressure, history of stroke, 
diabetes, and B-type natriuretic peptide levels).
 Shorter telomere length increases the odds of having anaemia in CHF patients. 
This finding supports the hypothesis that cellular ageing in CHF contributes to the 
susceptibility to develop anaemia.
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INTRODUCTION
Anaemia is common and associated with a poor prognosis in patients with chronic 
heart failure (CHF).1, 2 Several factors in CHF contribute to the development 
of anaemia, including iron deficiency, renal failure, haemodilution, the use of 
angiotensinconverting enzyme-inhibitors, and bone marrow dysfunction.3-5
 Bone marrow cells derived from patients with CHF have decreased in vitro 
colony-forming activity.6 In addition, reduced functionality of bone marrow cells 
has been demonstrated in patients with coronary artery disease. This phenomenon 
is associated with shorter telomere length, a marker for cellular ageing.7 
 The cause of the bone marrow dysfunction in patients with cardiovascular 
disease has not been elucidated, but has been suggested to originate from accelerated 
cellular ageing.7 If shorter telomere length in the haematopoietic bone marrow stem 
cells impairs function and proliferative capacity, this might indeed lead to decreased 
erythropoiesis and consequently anaemia. Telomere length of bone marrow cells is 
closely reflected by that of the easily accessible circulating leukocytes.7 Therefore, 
we explored the potential association between reduced leukocyte telomere length 
and the presence of anaemia in patients with CHF.
METHODS
This study was a substudy of the Coordinating study evaluating Outcomes of 
Advising and Counseling in Heart Failure (COACH) of which the main findings 
have been published.8-10 In brief, patients were eligible when 18 years of age or older, 
and had typical signs and symptoms of heart failure and evidence of structural 
heart disease. COACH enrolled both patients with impaired and preserved ejection 
fraction. In total, 875 (86%) of the 1023 patients from the COACH study participated 
in this substudy. The non-participating patients (n = 148) were excluded based on 
missing DNA samples (n = 133) and missing haemoglobin (Hb) values (n = 15). The 
Medical Ethics Committee of each participating centre approved both the main 
COACH study and this DNA substudy.
 According to the World Health Organization criteria, anaemia was defined as 
Hb levels <13.0 g/dL for men and <12.0 g/dL for women.
Storage conditions of blood and DNA and DNA isolation
Venous blood samples were collected into tubes containing EDTA and stored 
immediately at -80˚C. It has been shown that long-term storage of whole blood 
samples at this temperature does not influence yield or quality of leukocyte DNA.11 
DNA was isolated using the Qiagen QIAmp® 96 DNA Blood kit (Catalog number 
51162, Qiagen, subsidiary Benelux B.V. Venlo, The Netherlands; disposables Greiner 
Bio-One B.V.). Briefly, 200 mL of lysis buffer was added to a mixture of protease and 
200 mL of blood, and incubated for 10 min at 56˚C. Subsequently, 200 mL of ethanol 
was added to precipitate DNA, and DNA was bound to the silica-gel membrane of 
the QIAmp 96-well plate. Two washing steps followed, and finally DNA was eluted 
in 200 mL of elution buffer containing 10 mM Tris–Cl and 0.5 mM EDTA, pH 9.0. 
 DNA was stored at -80˚C after isolation and thawed at 4˚C before the 
CHAPTER 2
38
quantitative polymerase chain reaction (qPCR) measurements on telomere length 
were performed. All qPCR measurements were completed within 4 weeks. Storage 
of DNA at 4˚C for this short time period does not influence DNA quality.11, 12
Laboratory measurements
Serum creatinine and urea levels were measured with a colorimetric assay (Roche/
Hitachi Modular P analyzer). Haemoglobin levels were measured on the automated 
haematology analyser (Sysmex XE-2100). B-type natriuretic peptide (BNP) was 
measured using a fluorescence immunoassay kit (Triage®, Biosite Incorporated, San 
Diego, CA, USA). Erythropoietin (EPO) levels were determined with the Immulite 
2500 Erythropoietin assay.
Telomere length
Mean telomere length was measured by qPCR in leukocytes, as described 
previously.13, 14 Telomere length is expressed as T/S ratio, with ‘T’ being the telomere 
repeat copy number and ‘S’ the single gene copy number; in our study, this was the 
36B4-gene. The qPCR thermal cycling profile was the same for both T and S, and 
began with a 95˚C incubation period for 15 min. Forty cycles of 15 s at 95˚C and 1 
min at 58˚C followed. The specificity of all T and S amplifications was determined by 
melting curve analysis. All measurements were performed in triplicate on separate 
qPCR plates, but in the same well positions. T and S reactions for each sample were 
also done in the same well position to eliminate position-dependent effects on the 
measurements. The mean ± standard deviation (SD) coefficient of variation between 
three measurements was 7 ± 5% for the T assay and 6 ± 4% for the S assay.
Left ventricular and renal function
Left ventricular ejection fraction (LVEF) was determined mainly by 
echocardiography. A small subset of LVEF data were obtained by MUGA scan or 
gated SPECT. 
 At enrolment, renal function of all patients was estimated [estimated 
glomerular filtration rate (eGFR)] using the simplified modification of diet in renal 
diseases equation [186.3 x (serum creatinine/88.4)-1.154 x age-0.203, in women multiplied 
by 0.742].15
Statistical analysis
Telomere length ratio and BNP levels were natural log transformed because of the 
skewed distributions. The log-transformed values were used in all further analyses 
on telomere length and BNP.
 Baseline characteristics were compared between anaemic and nonanaemic 
patients by independent sample t-test or χ2 test as appropriate. We used standard 
logistic and linear regression analysis for anaemia and Hb levels, respectively. 
The relationship between Hb levels and leukocyte telomere length cannot be 
assumed to be linear, and therefore, we also modelled it as a fractional polynomial 
function [a local mean (0 degree) polynomial smooth at 95% CI level based on the 
Epanechnikov kernel function evaluated at 50 points]. Two-sided P-values of < 0.05 
were considered statistically significant. Statistical analyses were performed with 
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the use of STATA version 10.0 for Windows software (StataCorp LP, College Station, 
TX, USA). 
RESULTS
Baseline characteristics according to the presence or absence of anaemia are 
presented in table 1. The study population consisted of 61% males. Median age was 
73 years, median eGFR 53 mL/min/1.73m2, median LVEF 30%, and most patients 
were in NYHA class II and III. Patients with anaemia were older, had a lower eGFR, 
longer history of heart failure, higher LVEF, higher BNP levels, lower diastolic blood 
pressure, and a more frequent history of diabetes mellitus and stroke (table 1).
 
Table 1. Baseline characteristics





Hemoglobin (g/dL) 11.4 [10.5-12.1] 14.3 [13.4-15.2] 13.5 [12.2-14.8]
Telomere length 
   (T/S ratio)
0.65 [0.55-0.81] 0.71 [0.60-0.87] 0.69 [0.59-0.86] <0.001
Age (years) 76 [68-80] 73 [62-78] 73 [64-79] <0.001
Male (n (%)) 161 (63) 374 (60) 535 (61)   0.38
eGFR (mL/min/1.73m2) 45 [32-61] 57 [44-71] 53 [40-68] <0.001
Creatinine (µmol/L) 135 [101-172] 108 [89-136] 113 [90-144] <0.001
Erythropoietin level (mIU/mL) 20.7 [16.3-25.1] 13.7 [11.7-15.8] 15.8 [13.8-17.7] <0.001
Age of onset CHF (years) 72 [64-79] 70 [60-77] 71 [61-77]   0.009
Body mass index (kg/m2) 26 [23-30] 26 [24-30] 26 [24-30]   0.14
Left ventricular ejection fraction (%) 33 [25-45] 30 [22-42] 30 [23-44]   0.04
NYHA class (n (%))
   II
   III











BNP (pg/mL) 697 [341-1140] 430 [185-836] 493 [222-952] <0.001
Heart rate (beats/min) 72 [64-82] 72 [64-80] 72 [64-80]   0.60
Blood pressure (mmHg)
   Systolic









Medical history (n (%))
   Myocardial infarction
   Hypertension
   Diabetes mellitus
   Atrial fibrillation/flutter





















Previous admission (n (%)) 97 (38) 176 (28) 273 (31)   0.004
Data is presented as “median [interquartile range]” or “number (%)”. The body-mass index is the 
weight in kilograms divided by the square of the height in meters. eGFR – estimated glomerular 
filtration rate, NYHA - New York Heart Association functional class, CHF – Chronic Heart Failure, 
LVEF – left ventricular ejection fraction,  BNP –  B-type natriuretic peptide
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Chronic heart failure was mainly due to ischaemic heart disease (n = 369, 42.2%). 
Other causes of CHF were dilated cardiomyopathy (n = 182, 20.8%), chronic 
hypertension (n = 128, 14.6%), valvular heart disease (n = 81, 9.3%), and hypertrophic 
and restrictive cardiomyopathy (n = 25, 2.9%).
 Telomere length in the anaemic group was significantly shorter than that in the 
non-anaemic group (P < 0.001) (figure 1). In univariate logistic regression analysis, 
anaemia was predicted by telomere length (table 2). This remained significant 
after adjustment for age and gender, and also after additional adjustment for other 
baseline imbalances (table 2).
 To give an indication of the significance of telomere length in our prediction 
model, we compared the effect of telomere length to that of renal function in 
predicting anaemia. In the multivariate model, the effect of 1 SD change in telomere 
length was approximately as large as a 35 mL/min/1.73m2 decrease in eGFR, a well-
known independent risk factor for anaemia.
 Supplementary linear regression analyses were performed to explore the 
continuous relationship between Hb levels and telomere length (figure 2). Shorter 
telomere length was associated with lower Hb levels (correlation coefficient = 
0.119, P <0.001). This remained significant after adjustment for age and gender 
[standardised coefficient β (Std β) = 0.095, P = 0.004], and after additionally adjusting 
for EPO level, eGFR, LVEF, stroke, diabetes mellitus, age of onset CHF, diastolic 
blood pressure, and BNP (Std β = 0.130, P = 0.011).
Figure 1. Telomere length in the anaemic vs non-anaemic group. Telomere length is 
expressed as Telomere/Single copy gene (T/S) ratio. The boxes represent median T/S ratio 
with 25th and 75th percentiles. Telomere length of anaemic patients with chronic heart 
failure is significantly shorter than non-anaemic patients.
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Since EPO is a major stimulating factor of erythroid proliferation of the bone 
marrow, we also performed a linear regression analysis of EPO on Hb levels. 
Haemoglobin level was indeed associated with EPO level univariately (correlation 
coefficient = -0.302; P < 0.001). This persisted after adjustment for age and gender 
(Std β = -0.281, P < 0.001), and after adjustment for telomere length, eGFR, LVEF, 
stroke, diabetes mellitus, age at onset of CHF, diastolic blood pressure, and BNP 
(Std β = -0.236, P <0.001). We did not find a relationship between telomere length 
and EPO level (correlation coefficient = -0.058; P = 0.177).
DISCUSSION
In the present study, we found that shorter telomere length is associated with an 
increased prevalence of anaemia in patients with CHF, whereas EPO level did not 
show such an association. One SD shorter telomere length was associated with the 
risk of anaemia comparable to a decrease in eGFR of 35 mL/min/1.73m2.
 Anaemia is a frequent co-morbidity in patients with CHF and is related to poor 
prognosis.1 Anaemic CHF patients have a nearly doubled risk of death compared 
with non-anaemic patients and for each g/dL lower Hb level, the annual risk 
of mortality increases by 4.6%.2 On the other hand, polycythaemic CHF patients 
Table 2. Odds ratio for anaemia in univariate and multivariate logistic regression models.
Odds ratio 95% confidence interval 
for the Odds ratio
   p
Model 1 Telomere length (SD) 1.31 1.12 – 1.53   0.001



















History of diabetes mellitus



































  0.134  
NS = not statistical significant, SD = standard deviation, eGFR = estimated Glomerular Filtration Rate, 
LVEF = left ventricular ejection fraction, CHF = chronic heart failure, DBP = diastolic blood pressure, 
BNP = B-type Natriuretic Peptide
Model 1: relationship between telomere length and anaemia
Model 2: relationship between telomere length and anaemia, adjusted for age and gender
Model 3: relationship between telomere length and anaemia, adjusted for age, gender, and all baseline 
differences
The Odds ratio reflects the risk of having anaemia corresponding to a standard deviation decrease of 
telomere length, expressed as Telomere/Single copy gene (T/S) ratio, a 10-years increase of age, being a 
male, a standard deviation increase of EPO level, a 10mL/min/1.73m2 decrease of eGFR, a 10% increase 
of LVEF, a history of stroke, a history of diabetes mellitus, a 10 year increase of age of onset of CHF, a 
10mmHg decrease of diastolic blood pressure, and a 100pg increase of serum BNP level
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with Hb levels > 15 g/dL are liable to worse survival as well.16 This indicates that 
strict regulation of Hb level in CHF can improve survival, and should be a point of 
attention in clinical practice. Unfortunately, anaemia in CHF is often multifactorial 
of origin or due to chronic disease, and is not readily amenable to therapy.17, 18
 There are several lines of evidence suggesting that shorter telomere length 
causes bone marrow dysfunction and possibly plays a contributory role in the 
development of anaemia.19-21 Dyskeratosis congenita and Fanconi’s anaemia are 
classical examples of diseases characterized by shorter telomere length.19, 20, 22 
Indeed, bone marrow failure and anaemia are the hallmark features of both diseases. 
Anaemia in patients with Fanconi’s anaemia was even more severe when annual 
telomere shortening rate was higher.21 In apparent healthy subjects, telomere length 
has also been independently associated with decreased red blood cell count, but not 
with other haematopoietic cell counts, such as leukocytes and thrombocytes.23 This 
is in line with the finding that the telomere length of haematopoietic progenitor 
cells is indicative of their erythroid proliferation capacity in vitro.24 Erythroid 
progeny of the haematopoietic progenitor cells with shorter telomeres showed a 
significantly lower number of population doublings compared with haematopoietic 
progenitor cells with longer telomeres.24 Interestingly, telomere length did not affect 
proliferation of other haematopoietic cell lines.24
 Taken together, these data show that short telomere length is associated with 
the impairment of erythroid proliferation. This could be an additional causal factor 
for the high prevalence of anaemia in CHF patients, besides the established risk 
factors. In our study, the anaemic group was on average 3 years older than the non-
anaemic group. We observed an association of age with telomere length, with a 
0.0038 ± 0.0007 decrease in the T/S ratio per year increase in age. In multivariable 
adjustment, we confirmed that the slight difference in age between the anaemic and 
non-anaemic groups does not explain the association between telomere length and 
the risk of anaemia.
 The cause of telomere shortening in CHF is still unclear. Short telomeres could 
be causally related to the development and progression of CHF, but could also be a 
consequence of CHF-associated factors, such as a history of hypertension, increased 
oxidative stress due to activation of the renin–angiotensin system25, 26, or prolonged 
systemic hypoperfusion due to ventricular pump failure.27 In-depth research into 
the precise effects of telomere attrition on CHF and risk factors is needed to draw 
more definite conclusions about the nature of this relationship.
Telomere length could also possibly serve as a new biomarker for severity of 
CHF and a predictor of anaemia in CHF. Of course, large prospective studies on 
progression of CHF and incidence of anaemia are mandatory to determine the 
clinical applicability of telomere length as a novel biomarker.
 Over the past few years, it has become common to use qPCR to determine 
telomere length. Several studies have compared the results of qPCR with the 
previously frequently used telomere restriction fragment (TRF) analysis by 
Southern blotting. The correlation coefficient between T/S ratio and TRF estimated 
that telomere length is high (r between 0.65 and 0.82).13, 28, 29 Thus, using qPCR 
for measuring telomere length is reliable and, in addition, has several practical 
advantages compared with TRF analysis. 
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 A limitation of our study might be the measurement of telomere length in 
circulating leukocytes, and not in bone marrow cells, which are more difficult to 
obtain. However, it has recently been shown that telomere length of circulating 
leukocytes strongly correlates with telomere length of bone marrow cells (r = 0.75, 
P < 0.001).7 Secondly, our study was performed in a crosssectional manner and 
therefore conclusions about the character of the observed association—causal or 
only associative—cannot be drawn.
 In conclusion, we demonstrate that shorter telomere length is associated with 
an increased risk for the presence of anaemia in CHF patients, even when adjusted 
for age, renal function, and other potential confounders. The effect of one standard 
deviation shorter telomere length is comparable to a 35 mL/min/1.73m2 decrease in 
eGFR. These findings support the hypothesis that short telomere length contributes 
to the susceptibility to develop anaemia in patients with CHF. Further research on 
telomeres and their role in CHF is warranted, as a better understanding of telomere 
biology might reveal whether telomere shortening is cause or consequence in the 
pathophysiology of CHF, and this provides us with new therapeutic potentials for 
CHF.
Figure 2. Haemoglobin levels histogram and association with telomere length. The bars 
of the histogram represent haemoglobin levels (left Y-axis: percentage of subjects per bar). 
Black line represents the squared relationship between continuous haemoglobin levels and 
telomere length (right Y-axis: haemoglobin levels in mmol/L; X-axis: telomere length in 
ln(Telomere/Single copy gene (T/S) ratio). The shaded area indicates the 95% confidence 
limits as estimated by the fractional polynomial function. Longer telomere length correlates 
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Renal dysfunction is a frequent comorbidity associated with high mortality in 
patients with chronic heart failure (CHF). The intrinsic biological age might affect 
the ability of the kidney to cope with the challenging environment caused by CHF. 
We explored the association between leukocyte telomere length, a marker for 
biological age, and renal function in patients with CHF.  
 Telomere length was determined by a real-time quantitative polymerase chain 
reaction in 866 CHF patients. Renal function was estimated with the simplified 
Modification of Diet in Renal Disease (MDRD) equation.  
 The median age was 74 [inter-quartile range 64-79] years, 61% male, left 
ventricular ejection fraction of 30 [23-44]%, and the estimated glomerular filtration 
rate (eGFR) was 53 [40-68] mL/min/1.73m2. Telomere length was associated with 
renal function (correlation coefficient 0.123, p<0.001). This relationship remained 
significant after adjustment for age, gender, age of CHF onset (standardised-Beta 
0.091, p=0.007). Also additionally adjusting for the severity of CHF and baseline 
differences did not change our findings. 
 The association between shorter leukocyte telomere length and reduced renal 
function in heart failure suggests that intrinsic biological ageing affects the ability of 
the kidney to cope with the systemic changes evoked by heart failure.
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INTRODUCTION
Chronic heart failure (CHF) is an age-associated disease with a high prevalence and 
incidence in Western Society.1, 2 Risk factors associated with increased mortality in 
patients with CHF include hypotension, anaemia, increased BNP levels, activation 
of the renin-angiotensin system, and decreased renal function.3-10 The precise 
nature of renal dysfunction in CHF patients remains to be elucidated. It has been 
suggested that the decreased cardiac output, increased inflammation and oxidative 
stress may challenge the function and integrity of the kidney in patients with 
CHF.11, 12 At some point, a glomerulus may be irreversibly damaged, leading to 
“nephron dropout” and accumulating into a progressive decline of renal function. 
Recently, we provided preliminary data suggesting a possible association between 
shorter telomere length and reduced renal function in a retrospective study.13 We 
hypothesized that a more advanced intrinsic biological age, reflected by telomere 
length, increases the susceptibility of the kidney to lose function in the challenged 
physiological environment evoked by CHF.   
 Telomeres are considered indicators of biological age and are heritable 
structures located at the extreme ends of chromosomes. Telomeres consist of 
specific nucleotide repeats, in humans TTAGGG.14-16 In conjunction with several 
telomere-binding proteins, telomeres protect chromosomes from recognition and 
degradation by DNA damage signalling pathways.17 When telomeres become 
critically short, they lose their protective function and cells become genetically 
instable, causing senescence or apoptosis.14 Telomeres are incompletely replicated 
by DNA polymerase, causing cumulative attrition of length after each cell division 
and marking replicative history.16 Additional telomere attrition can be caused by 
damaging external factors (e.g., oxidative stress, activation of the renin-angiotensin 
system).18, 19 The aim of our study is to explore whether systemic leukocyte telomere 
length is associated with renal function in patients with CHF. 
METHODS
This study was a sub-study of the Coordinating study evaluating Outcomes of 
Advising and Counseling in Heart Failure (COACH) of which the main findings 
have been published.20, 21 The COACH study assessed the value of additional 
support by a specialised heart failure nurse in the treatment of CHF. Eligible 
patients were aged 18 years or older, had typical signs and symptoms, and evidence 
for structural heart disease confirmed by cardiovascular imaging. Patients did not 
necessarily have to have impaired left ventricular ejection fraction. At inclusion, 
patients were stable and on oral heart failure medication. In total, 157 (15%) of the 
1023 patients who participated in the COACH were not included in this sub-study, 
mainly because of no available DNA (N=133) or missing serum creatinine values 
(N=18). This study has been approved by the local Medical Ethics Committee. All 




Renal function and Telomere Length
Glomerular filtration rate (eGFR) was estimated at enrolment with the simplified 
Modification of Diet in Renal Diseases (MDRD) equation [186.3 x (serum 
creatinine/88.4)-1.154 x age-0.203, in women multiplied by 0.742], which is one of the 
most precise and accurate formulas for calculating GFR.22 A venous blood sample 
was taken from the patients during the first outpatient visit and DNA isolated 
from it according to standard protocols (Qiagen, subsidiary Benelux B.V. Venlo, 
The Netherlands; QIAmp 96 DNA Blood kit, catalogno. 51162). Mean leukocyte 
telomere length was measured by quantitative polymerase chain reaction (qPCR) 
in leukocytes, as previously described in detail.23 Telomere length is expressed as 
T/S ratio, which is the relative ratio of telomere repeat copy number “T” to a single-
gene copy number “S” (36B4). All samples were assayed in triplicates on separate 
PCR plates, but in same well positions. The mean±SD coefficient of variation was 
7±5% for the T-assay, and 6±4% for S assay.
Statistical analysis
Telomere length ratio was natural log transformed to obtain a normal distribution. 
Baseline characteristics were compared among quartiles of eGFR by one-way 
analysis of variance, Kruskis-Wallis test, or Chi square when appropriate. Pearson 
correlation coefficient was used to assess the association between leukocyte telomere 
length and renal function. Standard linear regression techniques were used to adjust 
for age and gender in a second model and additionally for age of CHF onset in a 
third model. This third basic model was used to subsequently adjust for baseline 
differences. Because renal function cannot be assumed to be linearly related to 
leukocyte telomere length, it was also modelled as a fractional polynomial function. 
A two-sided P-value of <0.05 was considered to indicate statistical significance. All 
statistical analyses were performed with use of STATA version 10.0 for Windows 
software (StataCorp LP, College Station, TX, USA).
RESULTS
Baseline characteristics according to quartiles of eGFR are presented in table 1. 
The study population consisted of 61% men, median age was 74 years, median left 
ventricular ejection fraction (LVEF) was 30%, with most patients in NYHA class II 
and III (together 97%). Patients with decreased renal function were less likely to be 
men, and more likely to be older of age, to have higher NYHA class, hypertension, 
diabetes, atrial fibrillation or flutter, lower hemoglobin levels, and a previous 
admission for CHF (table 1). 
 Estimated GFR decreased with age at a yearly rate of 0.70±0.058 mL/min/1.73m2 
(p<0.001). Telomere length ratio decreased steadily at a mean rate of 0.0035±0.00064 
per year of increase of age (p<0.001). 
 Telomere length was 0.719 (interquartile range 0.609-0.881) in the quartile with 
the highest eGFR, 0.710 (0.604-0.855) in quartile 2, 0.673 (0.582-0.834) in quartile 
3, and 0.667 (0.571-0.825) in the quartile with the lowest eGFR (p=0.031). When 
leukocyte telomere length was modelled as a continuous predictor, renal function 
decreased gradually with shorter telomere length. Pearson correlation coefficient 
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Table 1. Baseline characteristics
Patient characteristics Quartiles of estimated GFR (eGFR) Total P
1 (N= 216) 2 (N= 217) 3 (N= 216) 4 (N= 217) N= 866












































Male Gender, n (%) 148 (69) 140 (65) 134 (62) 107 (49) 529 (61) <0.001
NYHA class, n (%) 
    II
    III



















































    Systolic blood pressure


































Medical history, n (%)
    Diabetes 
    Hypertension 
    Myocardial infarction
    Atrial fibrillation/flutter
































    NT-pro-BNP (pg/mL)























Previous admission, n (%) 48 (22) 56 (26) 69 (32) 102 (47) 275 (32) <0.001
Current medication, n (%)
   RAS-inhibitors
   Beta-blockers
   Diuretics
   Digoxin































Normally distributed data is presented as means ± SD, skewed distributed data as median [interquartile 
range]. The body-mass index is the weight in kilograms divided by the square of the height in meters. 
eGFR – estimated glomerular filtration rate, NYHA - New York Heart Association functional class, CHF 
– Chronic Heart Failure, LVEF – left ventricular ejection fraction,  NT-pro-BNP - N-terminal pro-B-
type natriuretic peptide, RAS-inhibitors - renin-angiotensin-system inhibitors (angiotensin-converting 




for the association between telomere length and eGFR was 0.123 (p<0.001). The 
relationship between renal function and telomere length remained significant after 
adjustment for gender and age (standardised beta 0.090; table 2). In the third basic 
model we also adjusted for the age of CHF onset (figure 1). Our findings did not 
change after additionally adjusting for baseline differences (diabetes, hypertension, 
history of myocardial infarction, NYHA class, systolic blood pressure, diastolic 
blood pressure, heart rate, atrial fibrillation, NT-pro-BNP,  hemoglobin levels, use of 
renin-angiotensin system inhibitors, and digoxin; table 2).  
DISCUSSION
A frequent co-morbidity factor and powerful predictor of mortality in CHF 
is decreased renal function.4, 6, 7 The main finding of this study is that reduced 
leukocyte telomere length, as a marker for advanced intrinsic biological age, is 
associated with decreased renal function in patients with CHF. This observation 
remained significant after adjustment for several confounders, including age, age of 
CHF onset, and severity of CHF.
  Telomere length is associated with CHF. We recently demonstrated telomere 
length to be shorter in 620 patients with CHF compared to healthy controls.23 This 
was also observed by others.24 In addition, levels of TRF2 – one of the telomere-
stabilizing proteins – in the myocardium of heart failure patients was found to be 
down-regulated by approximately 50% compared to healthy controls.24 Interestingly, 
Werner et al. found that physical exercise in mice up-regulated TRF2, and protected 
Model 1: univariate. Model 2: adjusted for age and gender. Model 3; adjusted for age, age of heart failure 
onset, and gender. NYHA - New York Heart Association functional class, NT-pro-BNP - N-terminal 
pro-B-type natriuretic peptide, RAS-inhibitors - renin-angiotensin-system inhibitors (angiotensin-
converting enzyme and/or angiotensin-receptor blocker)
Table 2. Univariate and adjusted standardised beta for association between renal function and 
telomere length
Std-Beta 95%CI P-value
Model 1 0.123 0.057-0.189 <0.001
Model 2 0.090 0.023-0.157 0.008
Model 3 0.091 0.024-0.158 0.007
Model 3
  + Diabetes
  + Hypertension
  + Previous myocardial infarction
  + NYHA Class
  + Systolic blood pressure
  + Diastolic blood pressure
  + Heart rate
  + Atrial fibrillation/flutter
  + NT-pro-BNP
  + Hemoglobin
  + RAS-inhibitors
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the myocardium from doxorubicin-induced apoptosis.25 Thus, telomere biology is 
not only associated with CHF, but seems to be a modifiable factor in heart failure. 
Possibly, telomeres are a new therapeutic target in heart failure.
 A retrospective analysis of the cohort of 620 CHF patients suggested a 
potential association between telomere length and renal function.13 Obviously, 
retrospective analysis is susceptible to type-1 errors. The current prospective study, 
however, provides important independent confirmation of these preliminary 
findings. Reduced renal function might be associated with shorter telomere length 
in patients with CHF for several reasons. First, the processes in biological ageing 
and renal senescence associated with renal function decline include a decreased 
ability of aged nephrons to cope with diseased states. CHF elicits systemic changes, 
including decreased cardiac output, inflammation, oxidative stress, and activation 
of the renin-angiotensin system.9, 11 Nephrons with shorter telomeres might be less 
resistant to these challenges and more likely to enter a senescence state, become 
dysfunctional or even apoptotic. The phenotype of human renal senescence has 
indeed been described previously as the loss of mass and function, including a loss 
of glomerular filtration rate.26 Second, leukocytes telomeres mark replicative history 
and therefore might mark the cumulative inflammatory burden a patient has been 
exposed to.27 Inflammation is a major causal factor of vasculo- and glomerulopathy 
and consequently might cause a decrease in renal function. Finally, other factors 
associated with biological ageing (e.g., accumulation of advanced glycation 
endproducts) might cause renal dysfunction and coincide with shorter telomere 
length.28 
   The cross-sectional nature of our study does not allow drawing definite 
conclusions concerning the nature of the observed association. Although we used 
multiple statistical adjustments, we cannot exclude possible confounding factors 
that may have obscured the observed relationship. 
 In conclusion, decreased renal function was associated with reduced leukocyte 
telomere length in patients with CHF. This observation support the hypothesis that 
increased intrinsic biological age affects the kidney in its ability to cope with the 
systemic changes evoked by CHF and might explain, at least in part, why renal 
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Human telomeres attrition with age and short telomeres are associated with several 
age-associated diseases. There is considerable inter-individual variation in the 
rate of telomere attrition. Determinants of telomere attrition have not been fully 
elucidated.
 To identify determinants of telomere attrition, we measured a total of 
17,796 telomere length samples by multiplex monochrome real time quantitative 
polymerase chain reaction in all DNA available samples from  8,074  subjects 
collected on three occasions (at baseline, ~4.3 years, and ~6.6 years of follow-up). 
Multilevel growth models were created to identify factors influencing telomere 
dynamics.
 We observed an attrition rate of 0.57 ± 0.08 relative telomere lengths units 
(RTLU) per year. Telomere attrition rate was increased in older subjects, with a 
larger increase in males compared to females. The major environmental factors 
determining telomere attrition rate were smoking (-0.67 ± 0.16 RTLU per year (yr) 
smoking; P<0.0001) and multiple components of the obesity related metabolic 
syndrome (waist-hip ratio: -2.66 ± 0.99 RTLU per 1.0 ratio per yr; P=0.007, glucose 
levels: -0.76 ±  0.38; RTLU per mmol/L/yr P=0.045 and HDL-cholesterol levels: +0.91 
± 0.24 RTLU per mmol/L/yr P< 0.001).
 Smoking and the metabolic syndrome accelerate telomere attrition in humans. 
These modifiable factors may contribute to their adverse impact on risk of numerous 
age-associated diseases. 
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INTRODUCTION
Telomeres are the terminal ends of linear chromosomes, consisting of large 
numbers of tandem repeats of a simple DNA sequence (TTAGGG in humans), that 
are essential structures involved in maintenance of chromosomal stability and cell 
cycle control. In humans, the length of telomeres has been considered to mark the 
inter-individual variation of biological ageing for several observations: (1.) in vitro, 
somatic cells telomeres appear to shorten progressively with repeated cell divisions, 
(2.) there is a significant genetic determination and variation among individuals 
at birth and throughout life, and (3.) in vitro, the amount of telomere loss during 
each cellular division varies and is affected by environmental factors. When the 
mean telomere length reaches a critical value to produce inadequate telomeric end 
protection a DNA damage signal is generated which causes cell growth arrest or 
cell death. As such, telomere erosion is an important tumor-protection mechanism. 
However, a considerable number of studies have now shown an adverse association 
between shorter telomere length and other ageing-associated diseases, including 
atherosclerosis, coronary heart disease and heart failure.3-6  Patients with coronary 
artery disease have telomere lengths comparable to that of ~10 year older healthy 
individuals.4, 5 Several cross-sectional studies have shown an association between 
telomere length and demographic variables as well as life-style cardiovascular risk 
factors. However, such studies cannot establish whether such factors affect telomere 
attrition. This requires longitudinal studies with serial measurements of telomere 
length in the same subjects. Therefore we studied telomere length dynamics in a 
large population based cohort with longitudinal follow-up to identify the factors 
associated with temporal changes in telomere length. 
METHODS
Study population
This analysis was performed in the framework of the Prevention of Renal and 
Vascular End Stage Disease study (PREVEND; www.prevend.org). The PREVEND 
study is an ongoing longitudinal cohort study based on the general population 
aged 28-75 years in the city of Groningen, the Netherlands. For the present study, 
we excluded subjects of whom a venous blood sample for DNA isolation was not 
available at any time point. Details of the study have been described previously.7, 8 
In brief, 8,592 subjects completed the baseline survey (1997-1998) and were invited 
to visit the outpatient department at intervals of approximately three years. At each 
visit, demographic, anthropometric and serum biomarkers were assessed. Detailed 
information about the measurements and definitions used can be found in the 
supplementary methods section. The PREVEND study has been approved by the 
local medical ethics committee and is conducted in accordance with the guidelines 
of the Declaration of Helsinki. All participants provided written informed consent.
Telomere length measurement
To avoid any impact of variation in DNA extraction method on telomere length 
measurement, all samples analysed in the current study were (re)extracted 
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uniformly using the same DNA extraction kit (QIamp 96 DNA blood kit, catalog 
# 51162,  Qiagen, Venlo, The Netherlands) from non-defrosted full-blood samples 
according to the instructions of the manufacturer. DNA samples from different 
collection moments were mixed and randomly extracted to neutralise potential 
batch-effects. Samples with a DNA concentration > 70 μg/mL (determined by 
the nanodrop method) were diluted to reach a final concentration of 20 – 60 μg/
mL. Detailed information on the telomere length measurement is provided in 
the supplement. In brief, mean leukocyte telomere length was measured using a 
novel multiplex monochrome real time quantitative polymerase chain reaction 
technique.9 This technique allows carrying out the telomere specific amplification 
and the reference gene amplification in a single reaction well with quantification 
measurements at different temperatures.9 Samples were compared to a calibration 
curve which was run in triplicate on every plate, with a known and fixed DNA 
concentration. As negative controls water was used and as positive controls DNA 
was used of a human leukemia cell line (1301) which is known to possess very long 
telomeres (kindly provided by Dr. Cesaro, IST, Genova).  The ratio of telomere and 
household gene content (T/S ratio) is a Relative measure of Telomere Length (RTL) 
and is expressed in arbitrary Units (RTLU). All samples were  measured in triplicate 
and the average of the three runs was used to provide the mean RTLU for each 
individual. 
 We adhered to arbitrary categorisation of telomere trajectories previously 
reported (1.) RTL shortening, when >10% decrease of RTL was present at T3 
compared to baseline; (2.) 10% or less change of RTL at T3 compared to baseline, 
and (3.) RTL elongation for  > 10% increase in RTL at T3 compared to baseline.10, 11
Other measurements and definitions
All participants completed a questionnaire on demographic profile, cardiovascular 
disease history, medication use and smoking habits. Smoking was categorised 
as current smoking, stopped smoking and non-smoking. Additionally current 
smokers were divided in subjects smoking <6 cigarettes per day, 6-20 cigarettes/
day and >20 cigarettes/day. Blood pressure was measured with an automatic device 
(Dinamap XL model 9300, Johnson-Johnson Medical, Tampa Florida) in a supine 
position on the right arm. Hypertension was defined systolic blood pressure (SBP) 
of ≥ 140 mmHg or diastolic blood pressure (DBP) of ≥ 90 mmHg or the use of 
antihypertensive medication. Blood pressures were defined as normal when SBP < 
120 mmHg and DBP < 80 mmHg. Subjects in between were categorised as having an 
intermediate blood pressure. 
 The measured weight was divided by the height in meters squared to calculate 
the body mass index (BMI). Obesity was defined as having a BMI above 30 kg/m2. 
Subjects were categorised as non-obese when BMI was below 25 kg/m2. All subjects 
in between were categorised as intermediate. 
 Plasma glucose, serum creatinine and total cholesterol were measured by 
dry chemistry (Eastman Kodak, Rochester, New York). High density lipoprotein 
cholesterol (HDL) was measured using a homogeneous method (direct HDL, 
Aerosat TM system, Abbott Laboratories, Abbott Park, Illinois). Triglycerides 
were measured enzymatically. High-sensitivity C-reactive protein (hs-CRP) was 
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measured using nephelometry (BN II, Dade Behring, Marburg Germany). Insulin 
was determined with an AxSym® auto-analyzer (Abbott Diagnostics Amstelveen, 
the Netherlands).
 Diabetes was defined as a fasting plasma glucose level of ≥ 7.0 mmol/L (126 
mg/dL), non-fasting plasma glucose level of ≥ 11.1 mmol/L (200 mg/dL) or the 
use of oral antidiabetics. Hypercholesterolaemia was defined as having a total 
cholesterol of ≥ 6.5 mmol/L (250 mg/dL) or the use of lipid lowering medication. An 
optimal cholesterol was defined as ≤ 5.13 mmol/L (200 mg/dL). Subjects in between 
were classified as intermediate. Estimated glomerular filteration rate (eGFR) was 
calculated using the Modification of Diet in Renal Disease study equation taking 
into account sex, age, race and serum creatinine levels.5
Statistical analysis
To obtain a normal distribution telomere length was natural log transformed, 
and the 0,5% extreme values were characterised as outliers and omitted. Other 
continuous variables with a skewed distribution were also natural log transformed 
prior to further analysis.
 Differences in telomere lengths between groups were tested using student’s 
T-test or one way analysis of variance (ANOVA). Cross sectional associations of 
variables with telomere length were evaluated using standard linear regression 
models. Multivariate linear regression models were used to adjust for other relevant 
variables. To investigate telomere dynamics across time, two-level hierarchical 
growth models were constructed. Continuous variables were centred around the 
grand mean (e.g. the mean was set to zero) in order to improve interpretation of 




Baseline characteristics of the subjects studied are presented in table A. The 
median age at baseline was 48 [range 28 to 75] years with 50.1 % females and 94.9% 
Caucasian. At baseline (T1) telomere length could be successfully determined 
in 8,074 subjects (94% of available DNA samples). At baseline, shorter telomere 
length was associated with higher age, male gender, higher blood pressure, 
hypercholesterolaemia, diabetes, higher waist-hip ratio and body mass index, and 
cigarette smoking (tables 1 and 2).
Telomere dynamics
In addition to the baseline measurements (T1), we obtained 9,230 follow-up 
measurements from  2 moments of follow-up; 3,572 for the second time point (T2, 
on average at 4.3 years after T1) and 5,457 for the third time point (T3, which was 
on average 6.6 years after T1). Using the unconditional growth model we observed 
an average telomere attrition rate of -0.57±0.078 RTL per year in the longitudinal 
analysis, which is similar to the attrition rate derived from the cross-sectional 
analysis (-0.47 (-0.52 to -0.42)) (table 1). However, inspection of the data showed 
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considerable variation among individual telomere trajectories. In 44.1% of subjects 
RTL shortening occurred (defined as >10% decrease of RTLU), 21.9 % had a stable 
RTL trajectory (defined 10% or less change of RTLU) and in 34.0 % of subjects, 
we observed RTL elongation (defined as >10% increase of RTLU) after 6.6 years. 
Increasing age and male gender were again associated with a higher RTL shortening 
rate (figure 1). Furthermore, increasing age had a stronger effect in males. In our 
final basic model the annual telomere shortening for subjects with an average age 
and baseline RTL was 0.221±0.087 per year for females and 0.470±0.209 per year for 
males. For every 10 years of increasing age, the telomere attrition rate increased 
with 0.642±0.077 RTL for females and 0.850±0.179 RTL for males (table 3). Table S1 
details the modelling of age, gender, ethnicity and baseline RTL for our primary 
model providing the conditions in which further covariates were evaluated. 
Table 1: baseline values and association with baseline telomere length
Baseline-value 
(n=8074)
B (+ 95% C.I.) Standar-
dized B
p-value*
Age (years) 48 [39 – 60] -0.47 (-0.52 to -0.42) -0.205 <0.001
Male Gender (%) 4027 (49.9) -2.51 (-1.26 to -3.76) <0.001
Systolic blood pressure 
   (mm Hg)
126 [114 – 141] -0.030 (-0.066 to 0.006) -0.021 0.098
Diastolic blood pressure 
   (mm Hg)
73 [67 – 80] -0.029 (-0.102 to 0.043) -0.010 0.425
eGFR (mL/min.x 1.73m2) 78.8 [69.9 – 88.4] 0.0226 (-0.027 to 0.072) 0.011 0.368
Creatinin (µmol/L) 82 [74 – 92] -2.36 (-6.76 to 2.04) -0.014 0.293
Insulin (pmol/L) 8.0 [5.6 – 12.1] -2.00 (-3.03 to -0.97) -0.0424 <0.001
Glucose (mmol/L) 4.70 [4.30 – 5.10] -9.79 (-13.37 to -6.20 -0.0620 <0.001
Body Mass Index (kg/m2) 25.6 [23.1 – 28.4] -0.233 (-0.386 to -0.080) -0.0339 0.003
Waist-Hip Ratio 0.88 [0.81 – 0.95] -22.76 (-31.88 to -13.65) -0.0735 <0.001
C-reactive protein (mg/L) 1.29 [0.56 – 2.99] -1.82 (-2.38 to -1.26) -0.0732 <0.001
Cholesterol (mmol/L) 5.55 [4.89 – 6.32] -4.08 (-7.40 to -0.758) -0.0279 0.016
HDL-Cholesterol 
   (mmol/L)
1.27 [1.03 – 1.56] 6.28 (3.99 to 8.57) 0.0647 <0.001
Cholesterol-HDL ratio 4.36 [3.36 – 5.63] -5.38 (-7.25 to -3.51) -0.0679 <0.001








-2.20 (-3.37 to -1.03) <0.001
Data is presented as “median [interquartile range]” or “number (percentage)”. eGFR; estimated 
glomerular filtration rate, HDL; high-density lipoprotein, p-value after adjustment for age and gender.
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The effect of individual cardiovascular risk factors
We tested the role of individual cardiovascular risk factors by adding them to the 
basic growth model.
 Blood pressure: In the longitudinal analyses the binary trait of hypertension 
was not associated with telomere dynamics. However, both higher systolic (p=0.038) 
and diastolic (p=0.031) blood pressures were related to an increased telomere 
attrition rate (table 3). 
 Lipids: On a longitudinal scale, hypercholesterolaemia or elevated total and 
LDL-cholesterol level were not associated with increased telomere shortening. An 
increase of cholesterol/HDL ratio and triglycerides levels were related to increased 
telomere attrition rate (table 3). However a higher level of HDL-cholesterol was 
Table 2 : baseline RTL for subgroups





   Female  
   Male 
4047 (50.1)
4027 (49.9)
3.75 (2.85 to 4.64)
0.16 (-0.74 to 1.06)
1.026 (0.844 – 1.251)
0.982 (0.8179 – 1.201)
<0.001 <0.001
Race
   Caucasian
   Negroid
   Asian





1.68 (1.03 to 2.33)
12.46 (5.86 to 19.06)
5.86 (1.06 to 10.66)
5.89 (1.22 to 10.56)
0.999 (0.829 – 1.221)
1.111 (0.911 – 1.435)
1.019 (0.850 – 1.302)








   Yes
   Intermediate




-3.57 (-4.67 to -2.47)
3.68 (2.69 to 4.66)
5.81 (4.59 to 7.03)
0.949 (0.785  – 1.140)
1.026 (0.843 – 1.244)
1.042 (0.866 – 1.288)
<0.001 0.013
Diabetes
   Yes
   No
203 (2.5)
7871 (97.5)
-8.00 (-11.78 to -4.22)
2.22 (1.57 to 2.86)
0.915 (0.758 – 1.107)
1.004 (0.833 – 1.230)
<0.001 0.024
Obesity
   Yes
   Intermediate 




-2.28 (-3.83 to -0.72)
0.39 (-0.61 to 1.40)
4.85 (3.88 to 5.82)
0.963 (0.800 - 1.159)
0.984 (0.814 - 1.211)




   Yes
   Intermediate




-3.01 (-4.36 to -1.66)
1.58 (0.63 to 2.53)
5.73 (4.64 – 6.82)
0.956 (0.798 – 1.159)
0.996 (0.824 – 1.224)
1.048 (0.865 – 1.275)
<0.001 0.005
Smoking
   Yes
   Stopped




-0.44 (-1.53 to 0.65)
1.78 (0.72 to 2.84)
4.93 (3.78 to 6.09)
0.979 (0.812 – 1.198)
0.996 (0.828 – 1.218)
1.041 (0.856 – 1.266)
<0.001 <0.001
* for difference among groups
† adjusted age, gender and ethnicity where appropriate
‡ compared with Caucasians
IQR= interquartile range, HC= hypercholesterolaemia
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associated with a decreased telomere attrition rate (table 3, figure 1).
 Smoking: Smokers had a higher telomere attrition rate, than subjects 
who never smoked or who stopped smoking before the baseline measurement 
(table 3, figure 1).
 Diabetes: The presence of diabetes was associated with increased telomere 
attrition rate. Also higher levels of fasting glucose or insulin were associated with 
accelerated telomere attrition (table 3, figure 1).
 Obesity: Increasing BMI was associated with increased telomere attrition 
(table 3). The distribution of fat, as measured by waist-hip-ratio, was also associated 
with telomere attrition rate (table 3, figure 1).
Multi factorial model
Next, we tested a more complex model to explain telomere attrition rate by testing 
all the significant individual traits together. Non-significant variables were removed 
using a stepwise conditional backward strategy (for details see table S2). The final 
full model included baseline RTL, age, gender, age x gender, smoking, waist-hip 
ratio, glucose and HDL-cholesterol. In this model we found an annual attrition 
rate of 0.255±0.134 RTL for non-smoking females of average age (48 years). Every 
ten years of increasing age gave an additional shortening of 0.484±0.082 RTL 
and 0.695±0.188 for males. The other variables are gender independent and their 
estimates can be found in table 3 and figure 1.
DISCUSSION
Here we describe the first comprehensive evaluation of the determinants of telomere 
attrition in humans. Few studies have evaluated longitudinal telomere length 
dynamics and all previous longitudinal studies were insufficiently powered (up to 
662 subjects19) to adequately address the relationships of cardiovascular risk factors 
and longitudinal changes of telomere length. Previous small longitudinal studies 
have reported associations of waist hip ratio,10  HDL cholesterol,19 and smoking20 
but were unable to replicate each others findings. In the present evaluation 8,074 
subjects were studied on multiple occasions (17,796 total samples), providing 
the first convincing data demonstrating that blood pressure, body composition, 
smoking habits and glucose- and lipid metabolism are all associated with telomere 
length attrition rate over time, independent of age, gender and baseline telomere 
length. In addition, we also observed a significant gender effect, as was suggested 
previously.20 
 Our baseline cross-sectional data is in line with previous studies, suggesting 
an association with telomere length and age, gender, ethnicity12, 13, smoking14, 15, 
hypertension16 , body mass index15, 16 , waist-hip ratio10, 17 , insulin3, 16 , glucose16, 17 , 
total cholesterol18 , HDL-cholesterol19 , triglycerides18 , and CRP levels.3 
Based on cell cultures and cross-sectional measurements it has been assumed 
that telomere length of somatic cells can only become shorter in time. However, 
this dogma has recently been challenged by several studies measuring leukocyte 
telomere length on multiple occasions.10, 25, 26 Our data support earlier studies 
suggesting more dynamic changes, although the overall average length is likely to 
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Table 3: Estimates of annual telomere attrition rate
Model Variables included Estimate (95%) p-value
Unconditional Time (years) -0.571 (-0.725 to -0.418) <0.001
Basic model Time (years) -0.221 (-0.391 to -0.051)   0.011
Baseline telomere length 
   (RTLU)
-10.124 (-10.451 to -9.796) <0.001
Age (years) -0.064 (-0.074 to -0.054) <0.001
Male gender -0.249 (-0.485 to -0.013)   0.097
Age × male gender -0.021 (-0.041 to -0.001)   0.043
Hemodynamics  
factors
Systolic blood pressure 
   (10 mm Hg)
-0.074 (-0.143 to -0.004)   0.038
Diastolic blood pressure 
   (10 mm Hg)
-0.150 (-0.286 to -0.014)   0.031
Metabolic factors Insulin (pmol/L) * -0.215 (-0.420 to -0.011)   0.039
Glucose (mmol/L) * -1.290 (-2.006 to -0.575) <0.001
Diabetes 0.879 (0.127 to 1.631)   0.022
Body mass index (kg/m2) -0.035 (-0.063 to -0.007)   0.013
Waist-hip ratio -4.065 (-5.870 to -2.259) <0.001
HDL-cholesterol (mmol/L) * 1.264 (0.815 to 1.712) <0.001
Cholesterol-HDL ratio * -0.835 (-1.224 to 0.447) <0.001
Triglycerides (mmol/L) * -0.505 (-0.742 to -0.267) <0.001
Smoking Smoking† -0.728 (-0.428 to -1.028) <0.001
Full model Time (years) -0.255 (-0.526 to 0.015) <0.001
Baseline telomere length 
   (RTLU)
-10.703 (-11.039 to 10.367) <0.001
Age (years) -0.048 (-0.064 to -0.032) <0.001
Male gender 0.313 (-0.007 to 0.634)   0.055
Age x male gender -0.021 (-0.042 to -0.001)   0.047
Glucose (mmol/L) * -0.762 (-1.506 to -0.018)   0.045
Waist-hip ratio -2.658 (4.591 to -0.724)   0.007
HDL (mmol/L) * 0.912 (0.438 to 1.386) <0.001
Smoking † -0.675 (-0.982 to -0.367) <0.001
* estimate is for one increase in log transformed unit. † compared to non-smokers
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decrease in time. This observation supports the notion of the previous suggested 
homeostatic process of telomere length. Although all longitudinal studies conclude 
gradual telomere shortening on population level, most longitudinal data suggest 
telomere elongation in a percentage of subjects. Since telomere attrition rate is 
associated with various factors, characteristics of the population under study will 
probably influence this percentage. 
 Nevertheless, considering some of the potential shortcomings is also 
appropriate. Unavoidable to the longitudinal nature, DNA was collected at different 
time points and we cannot exclude potential collection conditions or other artefacts 
that might have ultimately affected the technique to measure telomere length. 
Surprisingly little is known on how these factors might affect the telomere integrity 
or measurement error making it difficult to control for it. In addition, the relative 
contribution of cell types (potentially harbouring different telomere lengths) making 
up full-blood DNA might temporarily change during the collection times. One of 
the limitations of our study is the large number of missing values in T2. Besides a 
natural lost to follow-up, the major reason for missing values is incomplete collection 
of whole blood for DNA isolation at T2 as it was initially thought not to be relevant 
to re-collect DNA samples. Because the date of visiting the outpatient clinic was not 
based on any of the subject’s characteristics, we concluded that the missing values 
were random. The little variation in ethnicity could also be considered a limitation.  
Although we observed ethnicity-specific differences in baseline RTL, we did not 
Figure 1: effect size on RTL change in the multifactorial model
The effects of the variables present in the full model on RTL change. The 0-line represents 
the basic attrition rate for non-smoking subjects when all other variables are at the mean. 
The boxes represent the additional telomere attrition rate for an increase of respectively: 10 
years for age, one standard deviation for glucose, waist-hip ratio and HDL. For smoking 
the box represents the additional telomere attrition for current smokers. The whiskers 
represent the 95% confidence interval for the estimates.
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find differences in telomere attrition rates. This is in concordance with previous 
reports.10 Aviv et al. reported faster telomere shortening in African Americans, 
which was probably caused by longer baseline RTL.26 This is in line with our results 
if one considers that our longitudinal RTL changes are adjusted for baseline RTL. 
Nevertheless, these collection differences and duration of storage differences are 
factors that are unavoidable factors of a longitudinal design and more likely will 
affect our quantitative estimates rather than our qualitative conclusions. 
 It is of great interest that, besides age and gender, the identified telomere length 
influencing factors are modifiable and suggest potential targets to decrease the 
telomere attrition rate. One could hypothesise that modifying smoking behaviour 
and obesity would lead to a slower pace of biological ageing, which is also in line 
with epidemiological evidence on life expectancy. One pilot study already provides 
suggestive evidence of increased telomerase activity after the implementation 
of comprehensive life style changes.21 Recently, marine omega-3 fatty acids were 
identified to reduce the rate of telomere shortening.11 These protective effects have 
been suggested to be caused by reducing oxidative stress on telomeric DNA22 and/
or telomerase.23, 24 Future studies will need to address the mechanisms of these 
interventions in more detail.
 In conclusion, we here present the largest study measuring telomere length 
to date and provide evidence for a longitudinal association of accelerated telomere 
attrition due to smoking, higher waist hip ratio, low HDL-cholesterol levels and 
high glucose levels. This notion support the hypothesis that smoking and the 
metabolic syndrome increase biological ageing pace.
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All laboratory work and PCR data analysis were performed without knowledge 
of clinical data. Mean telomere length was measured with the recently modified 
qPCR protocol using a single well strategy to measure both the telomere (T) and 
single reference (S) signal.1 All experimental DNA samples were assayed in 
triplicate which were measured on different plates but in the same well position. 
Samples of the three different time points were equally divided over our PCR 
schedule to prevent potential time- or seasonal influences.2,3 The ratio of telomere 
and reference gene content (T/S ratio) is a relative measure of telomere length. 
PCR reactions were set up by alliquoting 8μL of master mix into each well 
reaction of a 384-well plate compatible with our Bio-Rad CFX384 real-time system 
on a C1000 thermal cycler, followed by addition of 2μl DNA (~20ng), for a final 
volume of 10μL per reaction. Seven concentrations of a reference DNA sample 
(standard) spanning a ~12-fold range (5.2 to 60 ng) of DNA concentrations were 
prepared by serial dilution and analyzed in triplicate in every 384-well plate. Good 
linearity was observed across this range (R2 = 0.99). Two wells received water as 
the no template control (NTC), two wells were loaded with a human control 
sample and two with DNA of a human leukemia cell line (1301) with extreme 
long telomeres (kindly provided by dr. Cesaro, IST, Genova) as a positive/max 
control. The final concentrations of reagents in the PCR were 1U Titanium Taq 
DNA polymerase with the provided Titanium Taq PCR buffer, 0.75xSYBR Green 
I (Sigma), 0.2 mM of each dNTP, 1 mM DTT, 1M betaine, 900nM of each telomere 
primers (Telg and Telc), 900nM of each albumin (Albu and Albd). The primers were; 
telomere, telg, ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT 
and telc, TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA, 
that generate a short, fixed-length product (for a further explanation 
and details see Cawthon 2009).4 The S albumin primers were albu: 
CGGCGGCGGGCGGCGCGGGCTGGGCGGAAATGCTGCACAGAATCCTTG 
albd: GCCCGGCCCGCCGCGCCCGTCCCGCCGGAAAAGCATGGTCGCCT-
GTT. The predicted product size is 106 bp. Bold bases of the albumin primers are 
non-template 5’ tag sequences that confer a high melting temperature on resulting 
PCR product (for a further explanation and details see Cawthon 2009).5 The thermal 
cycling profile was Stage 1: 15 min at 95˚C; Stage 2: 2 cycles of 15 s at 94˚C, 15 s 
at 49˚C; Stage 3: 5 cycles of 15 s at 94˚C, 15 s at 66˚C; Stage 4: 32 cycles of 15 s at 
94˚C, 10 s at 60˚C, 15 s at 72˚C with signal acquisition, 10 s at 85˚C, and 15 s at 89˚C 
with signal acquisition. Stage 5; for QC a final dissociation stage was performed 
from 60˚C to 95˚C in steps of 0.05 s. At stage 4; the 72˚C reads provide Ct values 
for the amplification of the telomere template (in early cycles when the S signal is 
still at baseline); the 89˚C reads provided the Ct values for the amplification of the 
S template (at this temperature there is no signal from the telomere PCR product, 
because it is fully melted). For the reference DNA sample, each DNA concentration 
the Ct for albumin occurred ~ 7.2 cycles later in cycling than the Ct for the telomere. 
The Bio-Rad CFX manager software was used to generate two standard curves for 
each plate as previously described.6 For quality control all samples were checked 
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for concordance between triplicate values. Samples with a coefficient of variation 
(CV) of ≥ 10% within the triplicate were re-run. If the CV remained ≥ 10% the 
sample was omitted from the statistical analyses. Samples were run in triplicate 
and the intra-assay coefficient of variation was 2.0% (T), 1.85% (S) and 4.5% (T/S 
ratio). Reproducibility data was obtained for 216 subjects from PREVEND and good 
agreement between T/S ratios, measured on different days, was observed (r2=0.99, 
P<0.0001, inter-run CV 3.9%)7,8 (figure S1). T/S ratios of the three points in time were 
conformed to the great mean for every year of age, for interpretational and statistical 
reasons the median RTL was first centred around 1 and then log transformed. To 
improve readability each telomere length was multiplied by 100.
Measurements and definitions
Three different telomere trajectories were classified: 1) shortening, when RTL at 
T3 was decreased more than 10% compared to T1, 2) elongation in case of > 10% 
increase, 3) stable RTL for trajectories with ≤10% increase or decrease.9,10
 All participants completed a questionnaire on demographic profile, 
cardiovascular disease history, medication use and smoking habits. Smoking was 
categorised as current smoking, stopped smoking and non-smoking. Additionally 
current smokers were divided in subjects smoking <6 cigarettes per day, 6-20 
cigarettes/day and >20 cigarettes/day. Blood pressure was measured with an 
automatic device (Dinamap XL model 9300, Johnson-Johnson Medical, Tampa 
Florida) in a supine position on the right arm. Hypertension was defined systolic 
blood pressure (SBP) of ≥ 140 mm Hg or diastolic blood pressure (DBP) of ≥ 90 mm 
Hg or the use of antihypertensive medication. Blood pressures were defined as 
optimal when SBP < 120 mm Hg and DBP < 80 mm Hg. Subjects in between were 
categorised as having an intermediate blood pressure. 
The measured weight was divided by the height in meters squared to calculate 
the body mass index (BMI). Obesity was defined as having a BMI above 30 kg/m2. 
Subjects were categorised as non-obese when BMI was below 25 kg/m2. All subjects 
in between were categorised as intermediate. 
Plasma glucose, serum creatinine and total cholesterol were measured by dry 
chemistry (Eastman Kodak, Rochester, New York). High density lipoprotein 




cholesterol (HDL) was measured using a homogeneous method (direct HDL, 
Aerosat TM system, Abbott Laboratories, Abbott Park, Illinois). Triglycerides 
were measured enzymatically. High-sensitivity C-reactive protein (hs-CRP) was 
measured using nephelometry (BN II, Dade Behring, Marburg Germany). Insulin 
was determined with an AxSym® auto-analyzer (Abbott Diagnostics Amstelveen, 
the Netherlands).
Diabetes was defined as a fasting plasma glucose level of ≥ 7.0 mmol/L (126 mg/
dL), non-fasting plasma glucose level of ≥ 11.1 mmol/L (200 mg/dL) or the use of 
oral antidiabetics. Hypercholesterolaemia was defined as having a total cholesterol 
of ≥ 6.5 mmol/L (250 mg/dL) or the use of lipid lowering medication. An optimal 
cholesterol was defined as ≤ 5.13 mmol/L (200 mg/dL). Subjects in between were 
classified as intermediate. Estimated glomerular filteration rate (eGFR) was 
calculated using the Modification of Diet in Renal Disease study equation taking 
into account sex, age, race and serum creatinine levels.11
Model building strategy
The annual change in RTL over time was modelled as the dependent variable 
and variables of interest as covariates and factors. The hierarchy was modelled as 
follows: level one is the within-subject level consisting of the repeated telomere 
length measurements which are clustered in the second level which is the individual 
subject (between-subject level). This statistical technique is particular useful to 
explore longitudinal data, since the data of the repeated measures are clustered 
within the study subjects. In this way the first level is the respective measurement 
occasion (point in time) and the second level the individual subject. The benefits of 
this individual growth curve analysis are 1) it takes the dependency of longitudinal 
data into account by clustering it in the second level. 2) the technique is capable 
in handling unbalanced data (provided that the data is missing at random) 3) 
numerous numbers of waves (measurement occasions) can be used
The goodness of fit for the models constructed was evaluated using maximum 
likelihood comparison. The deviance of every model, defined as the -2 loglikelihood, 
was compared with the deviance of the former model. The model was classified 
statistically significant better when the change in deviance was greater than the 
critical value of the chi-square distribution for the relevant change in degrees of 
freedom. 
 First, an unconditional growth model was constructed which was then 
extended by variables classified as very likely to influence telomere dynamics over 
time by biological reasons or previous publications. In this basic model baseline 
telomere length, age, gender and ethnicity were introduced and their validity 
tested as can be read above. After having constructed the basic model our variables 
of interest were added to the basic model. Also interaction terms of the variables 
of interest with the variables of the basic model were sequentially included. All 
non-significant interaction terms were left out of the tables in the results section. 
All variables associated with telomere dynamics were then introduced into the full 
model. This model was constructed in a stepwise conditional backward manner by 
removing each variable and test whether the change in deviance with one degree of 
freedom was statistically significant.
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Table S1 Modelling of the basic model
Variables Decrease in 
deviance
Increase in df p-value*
Unconditional growth
Baseline RTL 2805.58 1
Baseline RTL + age 152.03 1 6.24 x 10-35
Baseline RTL + gender 8.04 1 4.66 x 10-3
Baseline RTL + ethnicity 3.96 3 0.266
Baseline RTL + age + gender 4.27 1 0.039
Baseline RTL + age + gender + age x gender 4.11 1 0.043
Basic model 3076.88 4
Table S2 Conditional stepwise backwards modelling of the full model
Omitted variable Increase in 
deviance
Decrease in df p-value*
Insuline 0.03 1 0.890
SBP 0.04 1 0.834
BMI 0.09 1 0.760
Triglycerides 0.35 1 0.552
Diabetes 1.42 1 0.233
Cholesterol-HDL ratio 0.96 1 0.327
DBP 0.94 1 0.332
Gender x age, gender 6.74 2 0.034
Full model 3.85 6 0.797
* p-value for significance of improvement of model. Df denotes degrees of freedom
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Telomere biology in cardiovascular 
disease: the TERC-/- mouse as a model 




Atherosclerosis and heart failure are major causes of morbidity and mortality in 
Western countries. Recent studies are suggesting involvement of telomere biology 
in the development and progression of age-associated conditions, including 
hypertension, atherosclerosis, and heart failure. Whether any of these reported 
associations are based on causal relationships remains to be elucidated. The 
construction of telomerase deficient (TERC-/-) mice might provide a potential 
instrumental model to study the involvement of telomere biology in cardiovascular 
disease. Here, we review the current available information from all studies 
performed in TERC-/- mice providing information on the cardiovascular phenotypic 
characteristics. Although this mouse model has proven its value in the understanding 
of the role of telomere biology in cancer, stem cell, and basic telomere research, only 
few studies were specifically designed to answer cardiovascular related questions. 
The TERC-/- mice provide exciting opportunities to expand our knowledge of 
telomere biology in cardiovascular disease and the potential identification of novel 
targets of treatment. 
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INTRODUCTION
Cardiovascular disease is the leading cause of morbidity and mortality in Western 
countries.1 Although experimental and epidemiological studies have identified 
many factors involved in pathogenesis of atherosclerosis and heart failure, our 
understanding is still incomplete. Recently, telomere biology has entered the 
cardiovascular research field as a potential factor involved in the initiation and 
progression of atherosclerosis and heart failure.2-5 Decreased telomere length has 
been associated with heart failure and atherosclerosis in human cross-sectional 
studies. However, there is no convincing human evidence implicating telomeres as 
a cause of atherosclerosis or heart failure. The construction of genetically modified 
mice with short telomeres provides an opportunity to increase our knowledge on the 
nature of the relationship between changes in telomere biology and cardiovascular 
disease. This mouse model has advanced our understanding of the role of telomeres 
in cancer, but there are only a few specific studies focuses on cardiovascular disease. 
Here, we will review all available information on cardiovascular phenotypic 
characteristics of the telomerase deficient mice. We expect that future experiments 
in these mice might help to fill in important deficiencies in our knowledge on the 
role of telomeres in cardiovascular disease. 
TELOMERE BIOLOGY
Structure and function of telomeres
Telomeres are the distal ends of chromosomes – present in all eukaryotes – 
and are made up of tandem repeats of specific DNA sequences (TTAGGG in 
vertebrates). The length of telomeres varies among and within species, but take up 
to approximately 15 kilobases in humans and 40 to 80 kilobases in mice.6 Telomeric 
DNA terminates in a 3’-single stranded overhang, which is well-protected in 
a three-dimensional structure, the so-called T-loop.5 Little is known about the 
dynamics of the T-loop formation, but it is clear that telomeric proteins are involved 
in this process. Telomeres associate with several proteins to form a telomere-protein 
complex, called the shelterin complex.7,8 Thus far, six telomeric proteins have been 
identified – the best-known proteins probably being Telomere Binding Factor 1 and 
2 (TRF1 and TRF2). Other telomeric proteins are Protection of Telomeres 1 (POT1), 
Ras-associated Protein 1 (Rap1), tripeptidylpeptidase 1 (TPP1), and TRF1- and 
-TRF2-interacting Nuclear Protein 2 (TIN2).8,9 As far as known today, these proteins 
do not have any function elsewhere in the cellular machinery.8 
Cellular signalling in response to telomere dysfunction
The essential function of telomeres is protecting the chromosomal ends from 
being recognised as double stranded DNA breaks. The protective mechanisms of 
telomeres are generally attributed to the unique features of the T-loop, as it hides the 
final open end of the DNA strand.  If telomeres become dysfunctional or critically 
short, they will lose their protective properties and several DNA damage signalling 
mechanisms will be activated. 
 In mammalian cells, DNA breaks will be marked by DNA damage foci 
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following phosphorylation of the histone H2AX sites by the protein kinases ATM 
(ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia- and Rad3-related).10 
ATM and ATR will also activate the DNA checkpoint kinases Chk1 and Chk2 
(which have an important role in cell cycle control). Chk1 and Chk2, in turn, will 
activate the anti-apoptotic protein p53 11, leading to the expression of p21, a cyclin-
dependent kinase inhibitor. P21 expression is linked to cellular senescence (figure 1). 
Activation of the checkpoint kinases can also lead to senescence, through inhibition 
of Cdc25 (cell division cycle 25). Next to the induction of senescence through p21, 
p53 can also initiate the apoptosis pathway.7,8 A far less well understood mechanism 
through which telomere dysfunction causes senescence is the induction of p16. In 
senescent human and mouse cardiomyocytes, telomere reduction was related to 
upregulation of p16.12,13,14 p16 blocks the cyclin dependent kinases CDK4 and CDK6. 
As a consequence, the protein RB (retinoblastoma protein) remains in its active, 
hypophosphorylated form. Active RB inhibits cell cycle progression and induces 
senescence (figure 1).7,15 
 In yeasts, the exonuclease 1 (EXO1) is shown to be involved in telomere-
associated cellular damage responses when telomeres become critically short.16,17 
Recently, a role for EXO1 in these damage responses has been confirmed in mice.18 
The role of EXO1 is discussed in more detail below.
 Cellular damage response initiated by telomere signalling can also involve 
DNA break repair systems. If telomeres are critically short or the shelterin complex 
is disturbed, the telomeric end will be recognised as DNA break in need of repair. In 
Figure 1. Schematic overview of some cellular signalling pathways in response to telomere 
dysfunction. 
POT1: Protection of Telomeres 1; ATR: ataxia-telangiectasia mutated; TRF2: Telomere Binding 
Factor 2; ATR: ataxia-telangiectasia- and Rad3-related ; Cdc25: cell division cycle 25; Cdk4/-6: 
cyclin dependent kinases 4 and 6; RB: retinoblastoma protein.
For details see text.7-11,15 
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response, two DNA repair mechanisms will come into action; 1.) non-homologous 
end joining (NHEJ) and 2.) homologous recombination (HR). NHEJ of telomeres 
results in chromosomal end-to-end fusion and causes further telomere damage 
and dysfunction. Both NHEJ and HR eventually will lead to cellular dysfunction, 
genomic instability and apoptosis (figure 1). More details on NHEJ and HR at 
telomeric ends are extensively reviewed elsewhere.8
 
Acquired telomere erosion
After every cell cycle, telomeres lose a number of telomeric base pairs. This 
phenomenon is also known as the “end-replication problem”. As a consequence, 
telomeres mark replicative history and are therefore considered a marker of 
chronological ageing.12,19,20 Telomere length of human peripheral white blood cells 
has indeed consistently been associated with age.21-24 Besides replicative stress, 
several external stressors have also been associated with telomere shortening. 
Most evidence exists for the telomere eroding effects of UV radiation and oxidative 
stress.25,26 Telomere length at any time is a resultant of length provided at birth, 
replicative and environmental stresses. Telomere attrition is variable and might be 
different during life time, but has been estimated to be on average approximately 30 
base pairs per year.27 
Structure and function of telomerase
Telomeres can be elongated by the ribonucleoprotein enzyme telomerase, which 
adds TTAGGG repeats to the 3’ end of DNA strands (figure 2). Telomerase consists 
of two core compounds, Telomerase Reverse Transcriptase (TERT) and Telomerase 
RNA Component (TERC), which serves as a template for addition of telomeric 
repeats to DNA strands.28 Under physiological circumstances, telomerase expression 
is undetectable in most human cells, with the major exceptions being embryogenic 
stem cells, germline cells, and certain epithelial and lymphoid progenitor cells.29,30 
Figure 2. Elongation of a telomere by telomerase.
Telomerase can elongate telomeres. Telomerase carries an RNA template that is used as a 
template to add telomeric nucleotide repeats, in human TTAGGG, to the 3’-ends of telomeres.
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TELOMERE BIOLOGY AND THE CARDIOVASCULAR PHENOTYPE IN 
HUMANS
Telomere length has repetitively been linked to cardiovascular disease states. 
One possible explanation for the association between telomere dysfunction and 
cardiovascular disease is that short telomeres lead to cellular dysfunction (e.g. 
diminished proliferative capacity) and increased senescence and apoptosis. 
Implications of diminished proliferative capacity for the cardiovascular system 
might include the exhaustion of the progenitor pool with repair capacity.31 As a 
result, neovascularization in ischemic heart disease and vascular regeneration in 
atherosclerotic disease could be limited. In addition, cellular stability is essential 
for maintenance of organ function, especially in scarcely regenerating tissue, such 
as the myocardium. Increased cellular vulnerability or actual increased senescence 
and apoptosis due to telomere dysfunction can promote heart failure. Alternatively, 
the association between telomere dysfunction and cardiovascular disease may be 
that the disease itself causes the telomere to dysfunction or shorten. So although 
the precise mechanisms connecting telomere biology to the different cardiovascular 
phenotypes remain to be defined, convincing lines of evidence are supporting a role 
for telomeres in cardiovascular (patho)physiology, and below we briefly summarize 
these data.
Telomeres and cardiovascular risk factors
Reduced telomere length is associated with the presence of cardiovascular risk 
factors.4 For smoking, the evidence is most convincing.32,33,34 Reduced telomere 
length is also associated with insulin resistance and obesity24,27,32, type 1 and type 
2 diabetes35,36, hypertension37, activation of the renin-angiotensin-aldosterone 
system38, and renal failure.39
Telomeres and atherosclerosis
Short telomeres have been implicated in vascular senescence and atherosclerosis.40 
Endothelial cells derived from atherosclerotic plaques have shorter telomeres 
compared to endothelial cells derived from non-atherosclerotic areas of the same 
individual.41,42 Patients with atherosclerosis also have shorter telomeres in their 
leukocytes compared to healthy, age-matched controls.41,43,44
Telomeres and heart failure
Evidence is accumulating involving telomere biology in the development of heart 
failure. In endomyocardial biopsies from patients with dilated cardiomyopathies 
more cells were senescent and telomeres were shorter compared to age-matched 
controls.13,45 Interfering with either function or expression of TRF2, one of the 
proteins that associate with telomeres, triggers telomere erosion and apoptosis in 
cardiomyocytes.45 As myocardial tissue is difficult to obtain, human studies have 
evaluated telomere length in circulating leukocytes. Telomere length of leukocytes is 
also shorter in patients with heart failure compared to healthy controls.43 Moreover, 
shorter telomeres have recently been found in bone marrow cells of patients with 
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atherosclerotic disease.46 Shorter telomere length in the bone marrow led to the 
speculation that it might affect the function of endothelial progenitor or other repair 
cells.31 
 The suggestion of the existence of cardiac progenitor cells (CPCs) as a repair 
source of the adult heart has raised the possibility that telomeres are important 
for the function of these cells.47,48,49 Telomere shortening is indeed observed and 
associated with aged and senescent CPCs.49 
 Unfortunately, despite significant clinical, in vivo and in vitro associations 
between cardiovascular disease phenotypes and telomere biology, definite proof for 
a causal role of telomeres in the development of atherosclerosis or heart failure has 
not been generated.
THE TELOMERASE DEFICIENT MICE
Telomerase deficient mouse models
The notion that mouse and human tumors express elevated levels of telomerase 
activity, while normal adjacent tissue lacks measurable activity, led to the 
development of models to study telomere biology. In 1997, dr. Maria A. Blasco 
reported the successful generation of telomerase deficient mice by knocking out the 
RNA template of telomerase (TERC-/- mice).50 This mouse model was established 
to serve as a tool to study tumor formation and cell viability in the absence of 
telomerase. Besides the RNA template, another essential component of telomerase 
is the telomerase reverse transcriptase (TERT). Not surprisingly, TERT-/- mice have 
also been constructed.
 Although originally generated to serve research related to oncology, the 
telomerase deficient mice have provided valuable information for ageing-associated 
diseases, including those related to cardiovascular disease. 
General phenotype of the telomerase deficient mouse
The telomeres of the TERC-/- mice shorten at a rate of approximately 5 kilobasepairs 
in every subsequent generation.50 Therefore, experiments using TERC-/- mice 
commonly involve several generations (G) of these mouse compared to wild types. 
Telomere length in G3 TERC-/- mice decreases as much as 50% during ageing from 
one to 16 months.51 TERC-/- mice of later generations show increasingly severe 
structural abnormalities on cellular level, including undetectable short telomeres, 
aneuploidy, and chromosomal end-to-end fusions.50 In general, animals with 
phenotypical features of ageing have shorter telomeres than age-matched controls 
from the same generation lacking a clear ageing phenotype. Later generations 
TERC-/- mice show a decreasing life span (table 1). Autopsy of late generation 
spontaneously diseased animals could not identify a clear cause of death, 
comparable to natural death in humans.51 Later generation and aged TERC-/- mice 
show many more defects than earlier generation and younger TERC-/- mice. These 
defects include reduced body size and weight, hair graying and loss, infertility and 
testicular atrophy, spleen atrophy, signs of immunosenescence, and bone marrow 
proliferative defects.51,52 Wound healing is also impaired in aged TERC-/- animals.51 
Reduced angiogenic potential of these mice has been suggested as an explanation 
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for this observation. Below we will focus in more detail on the knowledge of the 
angiogenic potential in these mice.
 Although some interesting studies have been performed on TERT-/- mice, these 
mice are substantially less well-studied compared to TERC-/- mice. The construction 
of the TERT-/- mice has first been reported in 1999.53 Both the TERT-/- and the 
TERC-/- mice do not show significant phenotypic abnormalities at early age in the 
first generation. Unfortunately, information on the general phenotype of the TERT-
/- mice of later generations is sparse and data on fertility of these mice are reported 
differently by different groups, possibly due to different backgrounds of the mice. 
Unchanged litter size in G1 and G2 TERT-/- mice (progeny from a chimeric and a 
wild type C57Bl/6 mouse) has been reported by some53, while others experienced 
dramatically reduced litter size in G2 TERT-/- mice on a pure C56Bl/6 background.54 
Indisputable is the fact that later generation TERT-/- and TERC-/- mice both have 
considerable shorter telomeres than their wild type litter mates.54,55,56 
 In general, homozygous TERT and TERC deficient mice display a similar 
phenotype. However, one remarkable difference between heterozygous TERT and 
TERC deficient mice has been observed. In contrast to TERC+/- mice, TERT+/- mice 
do not have detectable defects in telomere maintenance and elongation. In both 
heterozygous mice the mRNA levels of their knocked out gene are approximately 
30-50% of that of wild-type mice. The differences are therefore unlikely to be 
attributable to differences in target gene expression. Presumably, both TERC and 
TERT are essential for telomere maintenance and elongation, but in contrast to 
TERT, gene copy number and transcriptional regulation of TERC are limiting for 
telomerase activity.56,57
                                                                                        
Hypertension
Several cross-sectional human studies associate blood pressure parameters 
with telomere length of circulating leukocytes.37,58 Only one study is available 
evaluating blood pressure in telomerase deficient mice.59 In conscious mice, tail 
sphygmomanometry revealed that TERC-/- mice from G1 showed higher systolic 
blood pressures compared to wild type. In G3 mice, both systolic and diastolic 
blood pressure were increased compared to wild type and G1 mice. Studying 
anaesthesized G3 and wild-type mice with invasive haemodynamic studies did 
not show functional modifications in the nitric oxide system or the responsiveness 
to angiotensin II. Thus, the differences in blood pressure do not seem to be 
attributable to these two systems. Interestingly, the response to endothelin – a 
powerful vasoconstrictor – was diminished in G3. In concordance, treatment with 
bosentan, an endothelin receptor antagonist, resulted in a more pronounced drop of 
blood pressure in G3 mice compared to wild type. Furthermore, plasma and urine 
endothelin levels were gradually and significantly increased in G1 and G3 mice. To 
further explore the role of endothelin in the observed differences in blood pressure 
between TERC-/- and wild type mice, mRNA expression of endothelin converting 
enzyme (ECE) was measured. TERC-/- mice showed higher mRNA expression of 
ECE-1 and specific inhibition of ECE only reduced blood pressure in TERC-/- mice. 
In vitro experiments with transfection of deletion mutants of the ECE-1 promotor 
suggested that the AP-1 binding sequence of the ECE-1 promotor is involved, so 
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that transcriptional control of ECE-1 may be disrupted in TERC-/- mice.59 Whether 
long term treatment with endothelin receptor blockers is beneficial in TERC-/- mice 
remains to be determined. In addition, these functional data obtained in the TERC-/- 
mice have not been translated back to human studies, meaning we do not know yet 
whether ECE activity is also involved in the association between hypertension and 
telomere length in humans.
Atherosclerosis
The association between reduced telomere length in leukocytes with the 
development and presence of atherosclerotic manifestations in humans is 
demonstrated by several independent groups.41,44,60,61 As mice in general are resistant 
to the development of atherosclerosis62, many groups are using the apolipoprotein 
E (ApoE)-deficient mice, which do develop atherosclerosis when exposed to a high 
fat diet.63 Interestingly, ApoE-/- mice were inter-crossed with TERC-/- mice to study 
the effects of telomeres on the development of atherosclerosis.64 Fourth generations 
of TERC-/-ApoE-/-  and TERC+/+ApoE-/- mice were challenged with a high cholesterol 
high fat diet. Remarkably, generation four (G4) TERC-/-ApoE-/- mice developed less 
atherosclerotic lesions compared to G4 TERC+/+ApoE-/- mice (table 2). In addition, 
the atherosclerotic plaques of G4 TERC-/-ApoE-/- mice were morphologically in a less 
advanced stage of atherosclerosis, compared to G4 TERC+/+ApoE-/-. This suggests 
that the absence of telomerase activity is protective for atherosclerotic disease. These 
observations could not be attributed to differences in serum cholesterol levels.64 It 
was also observed that the proliferative capacity of macrophages and lymphocytes 
was decreased in G4 TERC-/-ApoE-/- mice compared to G4 TERC+/+ApoE-/-, suggesting 
reduced inflammatory capacity. This might explain the differences in atherosclerotic 
manifestations in this experimental model, since progression of atherosclerosis is 
partly dependent of functional immunocompetent cells.64 
 Experiments in these mice providing more definite proof, e.g., by a bone-
marrow switch with immune-competent cells or endothelial specific TERC-/-, have 
not been reported up to date. 
Angiogenesis
Evidence for involvement of telomerase in angiogenesis has been provided by 
adenovirus-mediated transfer of TERT in the rat hind limb ischemia, which enhances 
capillary density in the ischemic tissue.65 Also, TERC-/- mice have been studied using 
both matrigel implants and murine melanoma grafts.66 In an in vivo matrigel assay, 
late generation TERC-/- mice showed diminished angiogenic potential compared to 
wild type mice. Early generation TERC-/- mice, who have normal telomere length, 
did not have impairment of angiogenesis as assessed by the in vivo Matrigel assay.66 
This suggests that short telomere length limits the angiogenic potential, and not the 
absence of functional telomerase itself. Also an in vivo angiogenesis model using 
murine melanoma cells showed decreased tumor formation efficiency and growth 
rate in later generations TERC-/- mice. Microvessel density in tumor cryosections 
was stained with an anti-CD31 antibody – an endothelial cell marker – and it was 
shown that the microvessel density of G5 TERC-/- tumors was only half of the wild-
type and G2 TERC-/- tumors.66
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Cardiac myocytes and ventricular failure
The effects of telomerase deficiency on cardiac myocyte size, number, proliferative 
potential and myocyte apoptosis has been studied in combination with cardiac 
function in G2 and G5 TERC-/- mice of the original mixed background and 
compared to wild type mice. The progressive decrease of telomere length in 
cardiomyocytes of successive generations of TERC-/- mice was associated with an 
increase of p53 expression.67 G5 TERC-/- mice suffer from severe left ventricular 
failure, characterized by increased end diastolic left ventricular pressure, decreased 
maximally developed left ventricular pressure and disturbed contractility and 
relaxation of the left ventricle. These mice also showed anatomical changes of the 
heart, similar to dilated cardiomyopathy in human, together with decreased total 
number of myocytes and increase of myocyte hypertrophy. In addition, apoptosis 
of myocytes was an approximate 40% greater in G5 TERC-/- mice, compared 
to wild type and G2 TERC-/- mice.67 In G2 TERC-/- mice, only a slight decrease in 
left ventricular pressure compared to wild type mice was observed.67 These data 
suggest that late generation of TERC-/- mice spontaneously develop pathological 
cardiac remodeling and severe ventricular dysfunction. Another study showed that 
exercise increased TRF2 expression and prevented doxorubicin-induced cardiac 
apoptosis in wild type mice, but not in TERT-/- mice. This suggests that, in absence of 
telomerase, upregulation of telomere-stabilizing proteins is challenged and cardiac 
apoptosis is more severe.68
 In conclusion, telomerase deficient mice provide a model to study the efficacy 
of telomerase based therapies for heart failure. However, it should be taken into 
account that the majority of patients who develop heart failure have coronary artery 
disease. 
Stem cell biology and tissue regeneration
A key process in tissue and organ homeostasis is the mobilization of stem cells for 
maintenance and repair. Evidence is supporting a role for bone marrow derived 
cells in the maintenance and regeneration the endothelium.69 More controversial is 
whether the heart is also harbouring progenitor cells in adult life.48,49 The TERC-/- 
mice have provided us with more insights in the role of telomerase and telomere 
length in several well-characterized stem cell subtypes, including haematopoietic, 
epidermal, and neural stem cells. 
 Haematopoietic progenitor cells from G1 TERC-/- mice have a normal capacity 
to grow and differentiate in vitro. Mature haematopoietic organ structure and 
function seem to be well compensated in TERC-/- deficient mice, as no changes in 
peripheral blood count and profile were observed through successive generations 
and mature immunocytes show normal responses to mitogenic or infectious 
stimuli.70 However, in vitro haematopoietic colony-forming unit (CFU) assays 
revealed that later generation TERC-/- mice have a significant decrease in total 
number of CFU-granulocyte-monocyte, CFU-granulocyte, -erythrocyte, -monocyte, 
-megakaryocyte, and decreased high-proliferative-potential colony forming cell 
colonies.70 In addition, serial and competitive transplantations of TERC-/- bone 
marrow stem cells showed reduced long-term repopulating capacity compared to 
wild type cells.71,72 This indicates that long-term renewal of haematopoietic stem 
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cells is compromised upon telomere loss.
 In different generations of TERC-/- inbred mouse the epidermal stem cell 
number has been compared.73 In G1 and even more pronounced in G3 TERC-/- 
mice, greater numbers of epidermal stem cells were present in the bulge area of 
the hair follicle. Interestingly, the epidermal stem cells in TERC-/- mice showed a 
defect in their mobilization. Coincidentally, the proliferation index in different 
compartments was lower than that of wild-type follicles. In addition, in vitro 
culture of keratinocytes from G1 and G3 TERC-/- mice formed fewer and smaller 
colonies than those of wild type.73 Thus, epidermal stem cells in TERC-/- mice are less 
functional than in wild type, and the increased numbers of epidermal stem cells in 
the TERC-/- mice are possibly due to accumulation in the follicles, as the epidermal 
stem cells have impaired capacity to mobilize. 
 Although bone marrow and stem cells are considered important in the 
pathogenesis and possible treatment of cardiovascular disease, including 
atherosclerosis and heart failure, studies focuses on the role of telomere biology are 
lacking. In this regard also, the TERC-/- model provides a good model to study the 
efficacy of stem cell-based therapies for heart failure.
COUNTERACTING THE EFFECT OF TELOMERE DYSFUNCTION
As telomere biology is linked to cardiovascular pathology, targeting it provides 
new and promising therapeutic avenues to be explored. Here, we will discuss 
data investigating several possibilities of counteracting the deteriorating effects of 
dysfunctional telomeres.
Exonuclease-1 deletion
One of the proteins that mediate response to telomere dysfunction is exonuclease 1 
(EXO1).18 It has been shown that EXO1 deletion prolongs the lifespan of G3 TERC-/-
EXO1-/- mice, compared to G3 TERC-/-EXO1+/+ mice. EXO1 deletion preserves organ 
function of the intestinal tract and the haematopoietic system18, both organ systems 
that are normally affected in the TERC-/- mice.50 Remarkably, this beneficial effect is 
present in 12-15, but not 24 months old G3 TERC-/-EXO1-/- mice, suggesting that in 
old mice EXO1-independent mechanisms are responsible for the disturbed organ 
homeostasis. The beneficial effect of EXO1-deletion is not caused by preservation 
of telomere length. Telomere length in the G3 TERC-/-EXO1-/- mice is comparable to 
G3 TERC-/- EXO1+/+ mice. The precise mechanisms of the beneficial effects of EXO1-
deletion on mice with dysfunctional telomeres remain to be elucidated.
Telomerase upregulation
Under physiological circumstances, telomerase activity is absent or undetectable 
in the adult myocardium. Overexpression of TERT rescues telomerase activity 
and preserves telomere length in the adult mouse myocardium and induces 
cardiomyocyte hypertrophy, without fibrosis or impaired cardiac function. In 
addition, infarct size after experimental myocardial infarction was substantially 
reduced in TERT transgenic mice compared to wild type mice.74
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CONCLUSIONS AND FUTURE PERSPECTIVES 
Evidence in humans for an association between telomere length and cardiovascular 
related phenotypes, including atherosclerosis and heart failure, is rapidly 
accumulating.2,3,4,43 Understanding of the nature of these associations might be 
paramount in our understanding of the aetiology and pathogenesis of these diseases. 
Telomere biology already offers therapeutic targets in the treatment of cancer, but 
whether it can also provide novel therapeutic targets in coronary artery disease, 
heart failure, or optimalization of stem cells treatment remains to be discovered. 
For a rapid increment of our knowledge on the involvement of telomere biology 
in cardiovascular disease, the TERC-/- mice might turn out to be instrumental. 
Although this mouse model has proven its value in oncology, stem cell, and basic 
telomere research, up to date it is only sparsely used in the cardiovascular field. 
Studies with the TERC-/- mice might teach us valuable lessons on the involvement of 
telomere biology in age-associated hypertension, atherosclerosis, angiogenesis, and 
cardiac remodeling after myocardial infarction, as well as efficacy of telomerase and 
stem cell based therapies.
Table 2. Mouse models of telomerase manipulation and the cardiovascular 
phenotype
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We aimed to find support for the hypothesis that telomere length (TL) is causally 
involved in the pathogenesis of ischemic heart failure (IHF). We measured TL in 
IHF patients and their high-risk offspring and determined whether mean leukocyte 
TL reflects TL in CD34+ progenitor. We additionally measured TL of offspring of 
patients and controls to examine heritability throughout different cell types.
 TL was measured by qPCR in overall leukocytes, CD34+ progenitor cells, 
mononuclear cells (MNCs), and buccal cells in 27 IHF patients, 24 healthy controls 
and 60 offspring. TL in IHF patients was shorter than healthy controls in leukocytes 
(p=0.002), but not in CD34+ cells (p=0.39), MNCs (p=0.31) or buccal cells (p=0.19). 
Offspring of IHF patients had shorter TL in leukocytes than offspring of healthy 
subjects (p=0.04) but not in other cell types. Controls and offspring showed a good 
within person correlation between leukocytes and CD34+ cells (r 0.562; p=0.004 and 
r 0.602; p=0.001, respectively). In IHF patients and offspring the correlation among 
cell types was blunted. Finally, we found strong correlations between parent and 
offspring TL in all four cell types.
 Reduced leukocyte TL in offspring of IHF subjects suggests a potential causal 
link of TL in ischemic heart disease. However, this causality is unlikely to originate 
from exhaustion of TL in CD34+ progenitor or MNC cells as their lengths are not 
well captured by overall leukocyte TL. Additionally, we found strong correlations 
between parent and offspring TL in all examined cell types, suggesting high 
heritability of TL among cell types.
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INTRODUCTION
Telomeres are the terminal ends of the DNA strands, and shorten during life because 
of incomplete DNA replication after cell cycling or damaging environmental factors. 
Cells with critically short telomeres become dysfunctional, and can eventually 
even go into apoptosis.1,2 Recently, telomere biology has been implicated in ageing-
associated cardiovascular diseases. Most data has been generated on establishing 
the association between short mean overall leukocyte telomere length (TL) and 
ischemic heart disease (IHD).3-6 In addition, it has been suggested that presumably 
healthy offspring of patients with ischemic heart disease already have shorter TL 
compared to healthy offspring of controls.7 An open question remains whether 
telomere length is causally involved in the development of heart disease, and if so, 
what the underlying mechanism is. Short overall mean leukocyte telomere length 
has been viewed as a reflection of short telomere length in other cells, possibly of 
vascular progenitor cells, and thereby providing a link to an impaired vascular 
repair mechanism potentially causing ischemic heart disease. 
 To further dissect the association of ischemic heart disease with mean overall 
leukocyte TL we need to establish whether mean overall leukocyte TL is a reflection 
of TL in different cell types or whether it is more or less specific for leukocytes. 
Of particular interest in this regard are the CD34 positive (CD34+) cells as it is 
thought that these cells might be cardiovascular progenitor cells and play a role in 
cardiovascular repair.8-10 Short TL in CD34+ cells might provide a mechanism for 
the association with IHD as their cellular dysfunction might impair cardiovascular 
repair. Furthermore, mean leukocyte telomere length has not been compared to 
non-circulating non-vascular cells and it is unknown whether leukocytes might 
merely be a reflection of overall TL of the whole body.11
 We have investigated telomere length in circulating leukocytes, CD34+ cells, 
mononuclear cells, and the non-systemic non-circulating buccal cells in patients 
with ischemic heart failure (IHF) – which is the most extreme phenotype of IHD 
– and compared them to healthy, age-matched controls. Since occurrence of IHD 
is highly familial and telomere length is an inheritable trait12-14, we also aimed to 
determine whether telomere length in the different cell types is shorter in offspring 
of IHF patients compared to offspring of healthy controls. 
METHODS
Ethics statement
The study was approved by the local Medical Ethical Committee for human 
research of the University Medical Center Groningen (UMCG) and adheres to the 
Declaration of Helsinki. All participants were aged 18 or older and provided written 
informed consent for participation in this study.
Study design
The Telosophy study is an observational, prospective case-control study. Groups 
consisted of 1) patients with stable ischemic heart failure (IHF) and 2) age and 
gender matched healthy controls. In addition, of both groups we included offspring; 
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(3) offspring of IHF patients, and (4) offspring of healthy controls. 
 The inclusion criteria for the IHF patients were: presence of coronary artery 
disease (previous myocardial infarction and/or coronary revascularisation), left 
ventricular ejection fraction (LVEF) ≤ 40%, having heart failure for at least 6 months 
and being stable on optimal medication for heart failure for at least 4 weeks prior 
to the study visit, and having at least one healthy biological child that was willing 
to participate. Exclusion criteria were having had an ischemic cardiac event in the 
past 12 months and having severe cardiac valvular disease. Inclusion criteria for 
controls were being age- and gender- matched to the IHF patients, and having at 
least one healthy biological child who was willing to participate. Exclusion criteria 
for healthy controls were having known atherosclerotic disease or heart failure, 
a family history of premature cardiovascular disease, and having a partner (who 
is the biological parent of the participating offspring) with known cardiovascular 
disease. In addition, main exclusion criteria for all participants were having systemic 
inflammatory diseases, haematopoietic diseases, severe renal or liver disease, 
uncontrolled hypothyroidism, premature ageing syndromes, or malignancies, 
which could all influence telomere length. 
Study visit
IHF patients were recruited from the outpatient clinic of the Universitair Medical 
Center Groningen in Groningen, the Netherlands. Healthy controls were recruited 
with local advertisements or screened at the pre-operative outpatient clinic for 
planned selective non-cardiovascular surgery (small plastic surgery, ophtalmic 
surgery or minor orthopaedic procedures). 
 Subjects underwent 1 study visit to assess medical and family history and 
life style factors and to undergo a physical exam. Venous blood samples (60 mL 
in collected in tubes precoated with EDTA and 2.5 mL in the PAXgene Blood RNA 
tube, catalogno. 762174, Qiagen, Venlo, The Netherlands) and a buccal mucosa cells 
(four buccal swabs (isohelix, SK-4)) samples were taken. 
Isolation of CD34+ cells
Peripheral blood mononuclear cells were obtained from venous whole blood 
after density gradient centrifugation (Ficoll Paque Plus, catalogno. 17-1440-02, 
GE Healthcare Europe GmbH, Diegem, Belgium). The mononuclear cell (MNC) 
fraction was incubated with magnetic beads conjugated to anti-CD34-antibody 
(CD34 Microbead Kit, catalogno. 130-046-702, Miltenyi Biotec, Bergisch Gladbach, 
Germany). Subsequently, CD34+ cells were obtained from the MNC fraction by 
magnetic bead cell selection (MidiMACS separator, Miltenyi Biotec, Bergisch 
Gladbach, Germany). Flow cytometric analysis of mononuclear cells showed that 
incubation with anti-CD34-antibody and magnetic beads increased the CD34+ cell 
isolation from 0.39% to 58.81% (data not shown).
 
Telomere length measurement
DNA isolation of CD34+ cells, MNCs, and buccal swabs was performed according 
to manufacturer’s protocol (NucleoSpin Tissue kit, catalogno. 740952, Macherey-
Nagel/Bioké, Leiden, The Netherlands). Relative telomere length (TL) was assessed 
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by monochrome multiplex quantitative PCR method, previously described in 
detail15,16, and expressed as the ratio of telomere (T) to reference copies (S), further 
called T/S ratio. Samples of IHF patients, controls, and both offspring groups were 
randomly assigned to the plates and plate positions, with each plate containing 
samples of all four groups. All samples were run in triplicate. Samples with a 
coefficient of variation larger than 0.10 were run again. No samples had a coefficient 
of variation larger than 0.10 after the second run. 
 Data were characterised as outliers when >4 times standard deviation and 
were excluded from all statistical analyses (N=1).
Statistical analysis
Skewed variables were natural log transformed to acquire normal distribution. 
Differences in means between the groups were tested with Student’s T-test or Chi 
square test. Pearson (or Spearman) and linear regression techniques were used 
to asses associations between variables of interest. Multivariate linear regression 
analysis was used to make adjustments. All statistical analyses were performed in 
SPSS version 16.0 (SPSS inc. Chicago, Illinois). A two-sided p-value of <0.05 was 
interpreted to indicate statistical significance. 
RESULTS
Baseline characteristics
Baseline characteristics per group are presented in table 1. All IHF patients had 
experienced previous myocardial infarction. On average, IHF patients were aged 69 
years, had a mean LVEF of 27%, 85% was male, and were well treated.
 Offspring of IHF patients had a higher BMI and tended to have more frequently 
hypercholesterolaemia compared to offspring of controls.
Telomere length in leukocyte subpopulations in patients, controls, and their offspring 
In concordance with previous finding17,18 we observed shorter leukocyte TL in IHF 
patients compared to controls (figure 1). We also observed shorter leukocyte TL in 
offspring of IHF patients compared to offspring of healthy controls (figure 1). One 
of the aims of this study was determining whether telomere length of CD34+ cells is 
different in IHF patients compared to healthy controls. We did not find a difference 
in TL between IHF patients and controls in CD34+ cells (mean TL ± standard 
deviation 0.56 ± 0.17 and 0.60 ± 0.14, respectively, p=0.39). Also the TL of MNCs was 
similar (0.46 ± 0.12 and 0.49 ± 0.10, respectively, p=0.31) as were TL of buccal cells 
(0.97 ± 0.27 and 1.04 ± 0.19, respectively, p=0.19). In offspring, TL observed in CD34+ 
cells (0.66 ± 0.16 and 0.71 ± 0.16; p=0.22), MNCs (0.62 ± 0.17 and 0.62 ± 0.17; p=0.96), 
and buccal cells (1.17 ± 0.42 and 1.21 ± 0.25; p=0.47) were comparable. 
 These results clearly indicate that there is no significant difference in CD34+ 
cell TL between IHF patients and controls. CD34+ cell dysfunction as a result of 




Strong correlation between leukocyte and CD34+ in controls and their offspring, but not 
IHF patients and their offspring
Another aim of this study was to investigate whether within one individual the 
more frequently reported leukocyte TL mirrors TL of the cells of our interest, the 
CD34+ cells. Therefore, we examined the correlation between TL of leukocytes and 
CD34+ cells. Interestingly, we found strong correlations between TL of leukocytes 
and CD34+ cells in controls and their offspring but not in IHF patients or their 
offspring (table 2).
Table 1. Baseline characteristics














Age (years) 69 ± 6.9 66 ± 6.6 0.14 40± 6.8 38 ± 6.0 0.28
Male (n (%)) 23 (85) 20 (83) 0.86 17 (59) 9 (36) 0.10
Age of onset CHF (years) 60 ± 8.5 - - - - -
Body mass index (kg/m2) 28.0 ± 5.0 25.3 ± 3.0 0.04 27.2 ± 4.5 24.0 ± 2.4 0.002
Left ventricular 
ejection fraction (%)
27 ± 8.2 - - - -
NYHA class (n (%))
   II
   III















CRP (mg/L) 0.0 ± 0.0 0.0 ± 0.0 0.38 0.0 ± 0.0 0.0 ± 0.0 0.55









Heart rate (beats/min) 66 ± 8 67 ± 9 0.76 69 ± 13 71 ± 10 0.47
Blood pressure (mmHg)
   Systolic










 77 ± 13
0.64
0.71
Medical history (n (%))
   Myocardial infarction
   Hypertension
   Diabetes mellitus
   Atrial fibrillation/flutter
   Stroke






































   Beta-blocker
   ACE inhibitor and/or 
      AII antagonist
   Aldosterone antagonist
   Diuretic
   Statin
   Anticoagulant
26 (96)
  27 (100)




  3 (13)





























Data is presented as mean ± standard deviation or number (%). 
CHF – chronic heart failure; MNC – mononuclear cells; CD34+ – CD34-positive cells; The body-mass 
index is the weight in kilograms divided by the square of the height in meters; NYHA – New York Heart 
Association functional class; CRP – C-reactive protein; NTproBNP –  N-terminal proB-type Natriuretic 
Peptide; ACE – Angiotensin Converting Enzyme; AII – Angiotensin II. 
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Strong correlations between parent and offspring TL in all cell types
We found a positive association of TL between parent and offspring in leukocytes 
(correlation coefficient r 0.440, p=0.002). We also observed this association in CD34+ 
cells (r 0.401, p=0.004), MNCs (r 0.526, p<0.001), ), and in buccal cells (r 0.391, 
p=0.005) (figure 2). These associations remained significant after correction for age 
of parent and offspring (for leukocytes r 0.448, p=0.004, for MNCs r 0.547, p<0.001; 
for CD34+ cells r 0.397, p=0.004; for buccal cells r 0.368, p=0.010). We could not 
validate earlier findings suggesting an association of paternal age at time of birth 
with offspring telomere length.13
DISCUSSION
Shorter mean leukocyte TL is a remarkable and consistent finding in subjects with 
ischemic heart disease, but the reason is not known. Nevertheless, short overall 
mean leukocyte telomere length has been viewed as a reflection of short telomere 
length in other cells, possibly of vascular progenitor cells, and thereby providing a 
link to an impaired vascular repair mechanism potentially causing ischemic heart 
disease. We indeed observed a good correlation between overall mean leukocyte 
telomere length and CD34+, MNCs and buccal cells in healthy subjects and also 
in their offspring. However, these high intra-individual correlations were lost 
in subjects with IHF and their offspring. The major difference in telomere length 
between IHF patients and controls was observed in the overall leukocyte pool, 
not specifically in CD34+, MNCs or buccal cells as a source of non-blood derived 
cells. We confirmed earlier findings, suggesting shorter leukocyte telomere length 
in offspring of patients with coronary artery disease versus offspring of healthy 
controls.7 Finally, we confirmed the strong associations between parent and 
offspring TL in all four cell types we examined. 
 The comparable TL of CD34+ cells in cases and controls and both offspring 
groups are consistent with earlier findings19 and strongly suggest that telomere 
shortening of CD34+ cells is not a major player in the pathophysiology of IHD. If 
there is any role of TL in this process – the consistent finding of shorter leukocyte 
TL in IHD patients does support this allegation – it would rather involve other 
leukocyte populations. It is known that leukocyte function changes with ageing. 
In the elderly, specific immune responses might be diminished, but many other 
functions are unchanged or even augmented compared to young persons.20 A state of 
low-grade chronic inflammation has been recognised in elderly, which makes them 
prone to chronic inflammatory diseases, including atherosclerosis.20 Macrophages, 
and to a lesser extent other leukocytes, catalyse the process of atherosclerosis by 
eliciting an enhanced systemic inflammatory response, possibly through increased 
oxidative stress.20-22 Interestingly, it has been demonstrated that macrophages 
with short telomeres are more susceptible to damage from oxidative stress, and in 
addition have higher intracellular concentrations of oxidative stress molecules23, 
which are suggested to be a driving force in the development and progression of 
atherosclerosis.21 These data strongly suggest that ageing – chronologically or 




 A secondary focus of our study was the heredity of TL traits among cell 
populations. Heritability of mean leukocyte telomere length has been demonstrated 
previously.12,14,24 We now add to this the heritability patterns in TL derived from 
different cell fractions. A tissue specific TL regulation has been suggested, since TLs 
differ between different types of tissue.11 In addition, external influences on TL are 
acknowledged. For instance, it has been shown that vascular endothelial cells that 
endure more hemodynamic sheer stress have shorter telomeres than endothelial 
cells in low pressure arteries.25 Also, oxidative stress is a well-known factor that 
causes telomere shortening.26 Our results indicate that despite external influences 
and tissue specific TL regulation, TL is a highly inheritable trait throughout different 
cell types.
Table 2. Correlation coefficients between Cd34+ cells and other cell types within 
patients, controls, and offspring
Correlation coefficient r P-value
CHF patients 
Healthy controls 
Offspring of CHF patients









Figure 1. Mean leukocyte telomere length of all groups.
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Strengths and limitations
Our study is strengthened by the fact that we not only examined TL of IHF patients 
and controls, but also of their offspring. Our finding that TL in healthy offspring of 
IHF patients is shorter than in healthy offspring of controls supports the hypothesis 
that, next to the genetic predisposition to coronary artery disease deriving from 
specific genes, TL might also be a factor contributing to familial predisposition to 
IHD. Furthermore, we separated leukocyte cell fractions to determine differential 
expression of TL. This is significant, since knowledge on which specific cell types 
contribute to the shorter mean leukocyte TL is necessary in order to identify a 
potential mechanism underlying the association between TL and IHD. To our 
knowledge, our study is the first study that investigated both heritability features 
and differential expression of TL in leukocyte subpopulations. Also, our study was 
a prospective study, meaning all measures were taken in advance to preserve blood 
and tissue samples taken from participants, which contributed to high accuracy of 
experimental procedures and laboratory measurements.
 We also have to acknowledge some limitations. The separation of white blood 
cells was limited to MNCs and CD34+. Because of potential functional relevance, 
Figure 2. Correlations between parent and offspring telomere length in leukocytes (A), CD34+ cells (B), 
mononuclear cells (C), and buccal cells (D)
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our main interest was the CD34+ cell population. However, we demonstrated that 
the CD34+ cell population is not the cell population that drives the difference in 
leukocyte TL between IHF patients and controls. This difference must thus lie in 
other leukocyte cell populations that we did not separately analyse in this study. 
Conclusions 
In conclusion, we found that TL is shorter in leukocytes of IHF patients and their 
healthy offspring compared to healthy controls and their healthy offspring. This is 
supporting evidence for a causal role of TL in familial predisposition to ischemic 
heart disease. The fact that we did not find a difference in TL of CD34+ cells between 
IHF patients and healthy controls, suggests that these cells are not involved in the 
potential mechanism linking short TL and ischemic heart disease. Furthermore, 
we found good correlations between parent and offspring TL in all cell types we 
examined, indicating a strong inheritance pattern of TL. Evidence for a causal role 
of TL in ischemic heart disease will be helpful in finding new therapeutic targets. 
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During normal ageing, the heart undergoes functional, morphological and cellular 
changes. Although ageing per se does not lead to the expression of heart failure, it is 
likely that age-associated changes lower the threshold for the manifestation of signs 
and symptoms of heart failure. In patients, the susceptibility, age of onset and pace 
of progression of heart failure are highly variable. The presence of conventional risk 
factors cannot completely explain this variability. Accumulation of DNA damage 
and telomere attrition results in an increase in cellular senescence and apoptosis, 
resulting in a decrease in the number and function of cells, contributing to the 
overall tissue and organ dysfunction. Biological ageing, characterized by reduced 
telomere length, provides an explanation for the highly interindividual variable 
threshold to express the clinical syndrome of heart failure at some stage during life. 
In this review, we will elaborate on the current knowledge of ageing of the heart, 
telomere biology and its potential role in the development of heart failure. 
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INTRODUCTION
Congestive heart failure (CHF) is a highly prevalent condition affecting more than 
15 million patients in Europe alone.1 The incidence and prevalence of CHF increases 
steeply with age and is likely to rise in the next decade due to the increasing 
average age of the population.2 The prognosis of CHF is poor with a 4-year survival 
of only~50%.1 Advanced age is one of the major risk factors for the development 
of CHF. Nevertheless, the susceptibility, age of onset and pace of progression are 
highly variable. The presence of conventional risk factors cannot completely explain 
this variability. The process of biological ageing affects most cells, organisms 
and species. Although ageing itself does not need to lead to CHF, it is likely that 
age-associated changes lower the threshold for the expression of this syndrome. 
Significant changes in diastolic function, hypertension, atherosclerosis, valve 
calcifications, senile cardiac amyloid depositions all are associated with ageing 
and an increased risk of the clinical signs and symptoms of CHF.3 The molecular 
mechanisms involved allow time for accumulated damage to occur and include free 
radicals, advance glycation endproducts, apoptosis and senescence. Accumulation 
of DNA damage and telomere attrition can result in an increase in senescent cells 
in tissue and organs and can subsequently result in decreased function, providing 
an explanation for the lower threshold to express the clinical manifestation of 
heart failure. Here, we will briefly overview the current knowledge of the cardiac 
changes associated with ageing. One aspect of ageing in relation to CHF is of 
particular interest to us, telomere biology. Telomeres consist of an evolutionary 
conserved repetitive nucleotide sequence and are located at the terminal ends of 
the chromosomes.4,5 The process of telomere erosion has been put forward as an 
intracellular counting mechanism that runs parallel with the ageing process and the 
susceptibility to develop CHF.
FUNCTIONAL CHANGES OF THE AGEING HEART
At the functional level, there are no age-related changes in cardiac output, end-
diastolic or end-systolic volumes or ejection fraction at rest in healthy subjects.6 
However, the myocardial stiffness increases with advancing age, resulting in an 
elevated left ventricular end-diastolic pressure at rest and with exertion.7 Early 
diastolic filling is decreased in elderly, a phenomenon seen on echocardiography 
as a change of the early to late filling velocity (E/A ratio).8 Important age-associated 
changes are particularly noticeable during exercise. Although the stroke-volume 
increase during exercise of the young and old is comparable, the old tend to augment 
stroke volume during exercise more through cardiac dilatation with an increase 
in end-diastolic volume, whereas the young rely more on increase in the ejection 
fraction with no cardiac dilatation.9 During exercise, the older heart rate has a lesser 
increase in frequency and blood pressure has a greater increase.9 The difference in 
heart rate response is associated with a decrease in response to catecholamines and 
axonal degeneration of sympathetic neurons innervating the atria.10,11 In addition, 
the number of pacemaker cells in the sinoatrial node diminishes significantly, from 
around 50% in youth to less than 30% in elderly.12 One of the major vascular changes 
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during ageing is the decrease in aortic distensibility and decrease in the ‘Windkessel 
function’ explaining the frequently observed isolated systolic hypertension in 
elderly.7 
MORPHOLOGICAL AND CELLULAR CHANGES OF THE HEART
The mature myocardium constitutes of cardiomyocytes and supporting connective 
tissue.13 Healthy cardiac tissue is roughly composed of 20–25% cardiomyocytes, 
although this number varies among different species.13 During ageing, most 
components of the myocardium undergo structural changes. The change in 
morphology is characterized by a loss of myocytes number, with a subsequent 
hypertrophy of remaining viable myocytes.14 The remaining myocytes frequently 
contain multiple nuclei (polyploidy). The mechanism responsible for loss of 
myocytes is likely to be apoptosis, or programmed cell death. In parallel, there is an 
increase in collagen content, fibrosis and depositions of ‘senile’ cardiac amyloid and 
lipofuscin.15-17 Ageing cardiomyocytes display prolonged contraction and relaxation 
caused by changes in calcium homeostasis.18 Prolonged contraction with decreased 
force of the myofilaments is associated with down-regulation of genes that encode 
proteins that are involved in contractile activity, such as troponin and myosin forms 
in the aged heart.19,20 Age-related changes of the mitochondria include a tendency to 
become larger but less efficient, with a decreased ATP production per cell.21
CARDIOMYOCYTE TURNOVER DURING AGEING
The paradigm that all cardiomyocytes are terminally differentiated has been 
challenged. Recent experiments using human left ventricular myocardial cells and 
carbon-dating techniques have established that DNA of cardiomyocytes continues 
to be synthesized many years after birth, indicating that cells in the human heart 
do renew well into adulthood.22 Nevertheless, cardiomyocyte DNA synthesis 
decreases with age. Mathematical modelling predicts a ~1% cardiomyocyte renewal 
rate at the age of 25 and 0.45% at the age of 75. Considering this turnover rate, at 
the age of 50 years, 55% of the cardiomyocytes remain from the time around birth. 
There was no significant difference observed in 14C integration of DNA synthesis 
in cardiomyocytes from subjects with cardiac pathology. Interestingly, the 14C data 
also indicated a substantially higher renewal rate for non-cardiomyocytes, with a 
median annual turnover of 18%. Unfortunately, data derived from 14C integration 
do not allow the identification of the source of new cardiomyocytes. These could 
be derived either from cardiomyocyte duplication or from some sort of progenitor 
pool.22
 Advances in mouse genetic engineering allow cell tracking using ‘fate-
mapping’ approach. Cells expressing the cardiomyocyte-specific alpha-myosin can 
be genetically labeled by an inducible recombination technique leading to permanent 
GFP expression of only cells that expressed alpha-myosin at time of induction.23 If 
at a later stage, stem cells (which initially do not express alphamyosin) contribute to 
cardiomyocyte renewal or regeneration, the percentage of GFP-positive myocytes 
will decrease. These experiments indicated that stem cells do not replace adult 
121
Ageing, telomeres, and heart failure
mouse cardiomyocytes during at least 1 year of ageing. However, in the setting 
of myocardial infarction or pressure-overloaded hearts, a significant decrease in 
percentage of GFP-positive myocytes was observed, suggesting that precursor cells 
participate in the formation of new cardiomyocytes after injury.23 The bone marrow 
is a pool for multiple types of progenitor cells, which are believed to contribute to 
cardiovascular repair.24 Other possible sources of stem cells that can be stimulated 
to cardiogenic differentiation are located in adipose tissue or in the bone marrow.24
 One of the main determinants of functionality of bone marrow progenitor 
cells is age. A study in young and old bone marrow-derived endothelial progenitor 
cells (EPCs) showed that endothelial progenitor cells from 3-month-old donor 
mice augmented angiogenic capacity in the recipient 18-month-old mice, whereas 
EPCs from 18-month-old donor mice showed no effect.25 Furthermore, young 
mesenchymal stem cells (MSCs) showed higher angiogenic response to anoxia 
than old MSCs in vitro, and were more resistant to apoptotic stimuli.26 This was 
supported by a study in a myocardial infarction (MI) model. Infarct size of rats 
with experimental MI was attenuated after intramyocardial injections of young 
MSCs, whereas injection of old MSCs did not lead to any changes. In addition, 
cardiac function was preserved after MI in all rats that received MSCs—young, 
old or a mixture—but the beneficial effect on cardiac function was the largest in 
rats that received only young MSCs.26 Age does not only determine functionality 
of progenitor cells but is also possibly associated with the number of progenitor 
cells. 27-29
TELOMERE BIOLOGY
Telomeres are specialised DNA structures made up of tandem repeats (TTAGGG 
in humans) located at the end of chromosomes.4,5 Telomeres have a critical function 
as they serve as protective caps, preventing the chromosomal ends to be accidently 
recognised as DNA double strands by the DNA damage–repair system, and 
activation of the p53 or p16INK4a pathway, which eventually leads to senescence 
or apoptosis. The G-rich strand of the telomere, in conjunction with specialised 
proteins, form a so-called telomere loop (T-loop) concealing the terminal ends of the 
DNA strands (figure 1). These specialised proteins include telomeric repeat binding 
factor 1 (TRF1) and 2 (TRF2), which can both bind directly to double-stranded 
telomere DNA. Other telomere-associated proteins include the protein protection 
of telomeres 1 (POT1), binding directly to single-stranded telomere DNA, and 
repressor activator protein 1 (Rap1), TPP1 and TRF1-interacting nuclear factor 2 
(TIN2) (figure 2). Telomeres lose 30–150 base pairs during each cell division (also 
known as the end replication problem) due to the inability of DNA polymerase to 
fully replicate the 3’ end of the DNA strand. Additional erosion occurs in presence 
of damaging environmental factors, e.g., oxidative stress.30 Because telomere length 
marks the cumulative replicative history and cumulative exposure to environmental 
factors, it is strongly associated to date of birth (chronological) age and is even 
considered a marker of biological/cellular ageing. When the telomere reaches a 
critical short length, the cell will no longer divide and can become dysfunctional or 
senescent. On average, cells are estimated to reach senescence after ~50 population 
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doublings. Not only telomere length per se but also disruption of the associated 
telomere-binding proteins responsible for the three-dimensional loop structure can 
induce chromosomal instability, senescence or apoptosis.
 The function of the ribonucleoprotein enzyme telomerase is the elongation of 
the telomere sequence by addition of nucleotides to their ends. In most mature cells, 
telomerase activity is nearly undetectable, with exceptions including embryogenic 
stem cells, germline cells, malignantly transformed cells and some epithelial 
and lymphoid progenitor cells. Telomerase consists of two main components, 
telomerase RNA component (TERC) and telomerase reverse transcriptase (TERT). 
A third component (dyskerin) serves to stabilize the complex (figure 3). A less 
well-understood mechanism through which telomeres can be elongated has been 
named ‘alternative lengthening of telomeres’ (ALT). This mechanism is thought 
to be dependent on the cellular homologous recombination machinery, one of the 
systems for the reparation of DNA double-strand breaks. The ALT pathway is not 
an alternative to telomerase in cells that lack telomerase activity. Instead, the ALT 
pathway acts concurrently to telomerase.31
 Recently, the paradigm that telomeres are transcriptional silent has been 
Figure 1. Simplified scheme depicting the structure of the telomere and its location on the 
chromosome and in the cell.
Reproduced with permission.68
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Figure 2. Simplified scheme depiction the terminal end of the telomere concealing the terminal 
single-stranded part with help of the shelterin complex.
Reproduced with permission.68
broken. Telomeric repeat-containing RNA (TERRA) is an in length heterogeneous 
non-coding RNA forming an integral component of the telomeric structure.32,33 As 
the sequence of TERRA is complementary to TERC, it might be involved in the 
regulation of telomerase activity or regulation of the DNA damage response at 
short telomeres. However, the exact function of TERRA remains to be discovered.
 Telomere length is highly variable among individuals of the same age. Already 
at birth, remarkable differences in telomere length can be detected. Several studies 
have suggested that telomere length can be predicted by the telomere length of 
Figure 3. Schematic overview of telomerase. Active telomerase is composed from 2 RNA-
complexes (TERC; only 1 depicted) and 2 telomere-reverse-transcriptase (TERC; 1 depicted) 




the parents. Heritability of telomere length has been estimated to be as high as 
82%.34 The effect of paternal telomere length is more obvious than that of maternal 
telomere length. The strength of the association with paternal telomere length is 
in addition larger for father–son than for father–daughter relationships.35 Genome-
wide scans have mapped loci associated with telomere length on chromosome 1236, 
1437, 1838 and 3 near TERC (component of the enzyme telomerase).39
 Several environmental factors are also associated with telomere length and 
possible telomere attrition rate. Most important are oxidative stress30 and factors 
related to oxidative stress such as smoking40  and UV radiation.41 
TELOMERES AND HEART FAILURE
Telomere length has been related to factors predisposing to CHF, including 
hypertension42, diabetes mellitus43, premature myocardial infarction44 and activation 
of the renin-angiotensin-aldosterone system (RAAS).45 The effect of RAAS 
inhibition, however, is not clear, since presumably all patients that suffer from CHF 
are taking RAAS-inhibiting medication, leaving little or no CHF patients without 
RAAS-inhibiting mediation to serve as valid controls. Of course, the effect of RAAS 
inhibition could very well be investigated in an experimental heart failure model, 
but to date no data on this matter have been reported.
 Not surprisingly, patients with CHF also have shorter telomeres compared 
to healthy age- and gender-balanced controls.46 Telomere length has even been 
associated with the severity of CHF symptoms and outcome.46,47 In addition, worse 
renal function (a powerful predictor of outcome in CHF and not directly related 
to vascular function48-50) has been associated with telomere length in subjects with 
CHF.51,52 It is tempting to speculate this is also due to higher senescence in the kidney 
and consequently nephron dropout. In apparent healthy elderly, one standard 
deviation of shorter leukocyte telomere length was associated with 5% reduced left 
ventricular ejection fraction and telomere length alone accounted for 12% of the 
observed variability.53 Telomere length is usually measured in leukocytes but has 
also been evaluated in cardiac tissue from patients with CHF. Patients with dilated 
heart failure have ~25% shorter cardiac telomeres compared to healthy controls.54 In 
aged diseased hearts characterized by mild hypertrophy and biventricular failure, 
shorter average telomere length was found.55 Interestingly, cardiomyocytes with 
severely shortened telomeres (<2.5 kbp) were positive for p16INK4a, a marker for 
cellular senescence. The fraction of p16INK4a-positive cardiomyocytes was much 
larger in aged diseased heart compared to non-diseased controls. These findings 
are consistent with the idea that short telomere length is associated with increased 
levels of cellular senescence facilitating—if not causing—heart failure.55
 The most prominent question concerning the association between telomere 
length and heart failure is the causality of this association. Does short telomere 
length directly contribute to the development and progression of heart failure, or 
does short telomere length itself or the underlying cause of heart failure lead to 
accelerated telomere shortening? An attractive explanation could be that telomere 
dysfunction is a common pathway through which risk factors act and increase 
cardiomyocyte senescence and dysfunction. The diminished regenerative capacity 
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might also include exhaustion of the progenitor pool with repair capacity.56-58 
Evidence for a causal role has been provided by telomerase knockout mice. Fifth-
generation telomerase knockout mice have severely reduced telomere length 
and suffer from severe left ventricular failure, characterized by increased end-
diastolic left ventricular pressure, decreased maximally developed left ventricular 
pressure and disturbed relaxation and contractility very similar to that observed 
in human dilated cardiomyopathies.59 On the other hand, stabilizing telomeres by 
over-expression of TRF2 prevents doxorubicin-induced cardiac apoptosis in wild-
type mice, but not in telomerase-deficient mice.60 However, convincing evidence 
in humans for a causal role is lacking. Shorter telomeres could be a consequence 
or an epiphenomenon rather than a cause of CHF. Oxidative stress or increased 
inflammatory status, both related to outcome61, could provide a true basis of the 
development of CHF and at the same time explain reduced telomere length. 
CONCLUSIONS AND FUTURE PERSPECTIVES
Recent clinical CHF trials, for example with statins62, have not fulfilled their promises 
in improving prognosis of CHF.63,64 Therapeutic strategies to improve myocardial 
function and outcome in CHF are urgently needed, and new medicines are rapidly 
being introduced.65-67 Telomere biology might be involved in the biology of ageing 
and age-associated pathology. Telomeres are connected to the basic biology of 
ageing and trigger cellular senescence. It still needs to be established whether 
telomere biology is causally involved in the development of CHF in humans. Large, 
prospective, longitudinal studies are needed to provide us with more in-depth 
insights into the nature of the association between telomere length and CHF. These 
studies can clarify whether short telomere length predicts the development of 
CHF—which possibly supports a causal role—or telomere length merely shortens 
after manifestation of CHF. Of course, strongest evidence for a causal role would be 
delivered by interventional studies that demonstrate the cardiac effects of actively 
altered telomere length. At this time, however, this approach encounters not only 
several practical obstacles, but also moral objections, since our awareness of all the 
consequences of telomere length manipulation is surely incomplete. Nevertheless, 
answering the question on causality unambiguously in the near future is essential, 
as it will allow the development of novel strategies in the treatment and prevention 
of CHF, for example by beneficially modifying stem cells currently used in 
experimental trials. 
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Chronic heart failure (CHF) is a condition affecting millions of people, especially 
elderly, worldwide. Large scale investigations have contributed to the discovery of 
several risk factors for CHF, but the precise mechanisms of CHF have not fully been 
elucidated. 
Telomeres are the distal ends of our chromosomes. They consist of repeats of 
specific nucleotide sequences, enabling them to fold in to a special structure called 
T-loop. Due to this T-loop formation, the distal ends of our DNA strands are hidden 
and importantly protected from damaging external influences, like oxidative stress 
or UV radiation.
 In natural course of life, telomeres shorten gradually due to incomplete DNA 
replication and erosion. Cells with critically short telomeres have shown to become 
dysfunctional, senescent or even go into apoptosis. It is therefore not surprising that 
short telomere length can lead to organ dysfunction.
Approximately a decade ago, telomere length has been introduced as a possible new 
player in the pathophysiology of CHF. Clinical associations between short telomere 
length and CHF have been reported repetitively. However, suggested explanations 
for this association were only scarcely supported by scientific data. In this thesis, we 
investigated the association between short telomere length and CHF.
The first part of this thesis focuses on the clinical associations between telomere 
length and CHF.
 Chapter 1 provides an overview of the literature on the association between 
telomere length and CHF or risk factors. Short telomere length has repetitively 
been associated with atherosclerosis and myocardial infarction. Furthermore, it also 
has been associated with classic cardiovascular risk factors, such as hypertension, 
diabetes, and cigarette smoking. 
 Chapter 2 and 3 show that telomere length is associated with co-morbidities 
of CHF in patients. Chapter 2 reports the association of short telomere length 
with prevalence of anaemia, another frequently present co-morbidity of CHF. 
The question rises whether this is a causal relationship or not. Unfortunately, the 
cross-sectional approach of the study does not allow drawing any conclusions on 
causality. However, other studies have shown that short telomere length in the bone 
marrow impairs haematopoietic potential of bone marrow cells, and that leukocyte 
telomere length reflects bone marrow telomere length very well. Although this is 
indirect evidence, these data do suggest that the anaemia in CHF could be the result 
of a diminished proliferative potential of haematopoietic bone marrow cells with 
short telomeres. Chapter 3 describes the inverse association on telomere length and 
renal function, indicated by estimated glomerular filtration rate, in patients with 
CHF. There are several possible explanations for this association. Renal dysfunction 
causes increased oxidative stress. Oxidative stress is one of the recognised factors 
that induces telomere shortening. Telomere length would then serve as a systemic 
marker for damage originating from decreased renal function. Another possible 
example could however also be that short telomere length is a causal factor for 
development of renal dysfunction in CHF patients, assuming that leukocyte 
telomere length reflects telomere length of other cell types. Cells with short 
telomeres are possible more vulnerable for damaging environmental factors. Short 
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telomere in renal cells would then result in a cellular vulnerability in the kidney, and 
pose an increased risk on a CHF patient to develop renal failure. Chapter 4 describes 
the large, longitudinal study of telomere length in association with cardiovascular 
risk factors in time in approximately 8000 subjects without a cardiovascular history 
of disease. This is the first clinical study of this magnitude with telomere length 
measured at multiple time points. This study showed that telomere attrition rate 
was associated with the well-known cardiovascular risk factors smoking, obesity, 
and glucose levels. High HDL-levels are associated with a decreased telomere 
attrition rate. Based on these study results, one could hypothesize that the pace of 
biological ageing can be influenced by change in life style patterns, which is also in 
line with epidemiological evidence.
The second part of the thesis aimed at the possible mechanisms underlying the 
observed associations between short telomere length and CHF.
 Chapter 5 describes the telomerase deficient mouse model as a model for 
cardiovascular research. Telomerase deficient mice were originally generated 
for cancer research, as telomerase activity is often a key factor in the process 
of carcinogenesis. However, it also serves as an excellent model to explore the 
possible mechanisms connecting telomeres and cardiovascular disease. For 
fundamental research, non-human models are indispensable since highly controlled 
environments or genetic resemblance is often required to elucidate the precise 
influence of a factor of interest. In chapter 6, we investigated whether circulating 
cardiovascular progenitor cells would have shorter telomere length in CHF patients 
than healthy controls. We confirmed that leukocyte telomere length is shorter in 
CHF patients than in healthy controls, and demonstrated that this could also be 
observed in the healthy offspring of both groups. We also showed that telomere 
length was not different between CHF patients and healthy controls in circulating 
cardiovascular progenitor cells, making it very unlikely that these progenitor cells 
are involved in the role of telomere biology in CHF. 
 Finally, chapter 7 describes the ageing cardiovascular system and the role 
of telomere length in this ageing process, and it provides an overview of recent 
scientific findings on telomere length in relation to cardiovascular disease. 
Future perspectives.
The main question regarding the role of telomere length in CHF remains the nature 
– causal or not – of this relationship. Most evidence for this association comes from 
observational clinical studies. These studies have predominantly used leukocyte 
telomere length, presumably because of easy access (venous blood puncture) to 
leukocyte DNA.1-7 It is however not established whether short leukocyte telomere 
length reflects overall short telomere length, including short telomeres in the 
myocardium. In addition, we and others have shown that leukocyte telomere length 
within one individual can fluctuate in time. It would be interesting to see whether 
the association between telomere length and CHF extents to myocardial telomere 
length. This would give us a clue whether the potential mechanisms linking short 
telomere length and CHF is to be sought on cellular level within the myocardium 
or more systemic influences affecting both leukocyte telomere length and cardiac 
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function. However, as mentioned before, obtaining large numbers of human cardiac 
tissue samples is difficult. Therefore, the telomerase knock out mouse model 
could be of possible value. It would be interesting to see whether late generation 
telomerase knock out mice (with short telomeres) would develop heart failure after 
–for example- experimental myocardial infarction more rapid or severe compared 
to early generation mice with longer telomeres. It would also be interesting to 
see how both generation mice would respond to classic heart failure medication. 
Possibly, this could contribute to a more tailor-made medical treatment for patients 
with CHF.
 One could wonder what the clinical applicability of telomere length could 
be. This depends substantially on whether telomere length is causal to CHF. 
If causality can be established, one could think of telomere-stabilizing or even 
elongating therapeutic strategies. It has for example been suggested that statin 
treatment stabilises telomere length8, and that patients with coronary artery disease 
with shortest telomere length benefit most from statin treatment.2 Theoretically, 
it is possible to transplant cells with upregulated telomerase, and consequently 
longer lifespan, to enforce the compromised heart. However, repeated studies 
have pointed out difficulties with harbouring of circulating cells in cardiac tissue.9 
Another problem is the viability of these transplanted cells. This opportunity 
therefore sounds potentially promising, but has many obstacles to overcome and 
the beneficial effects are to be established.
 In another scenario, telomere length could serve as a biomarker for CHF. 
For diagnostic purposes it will probably not be useful, because of the large 
interindividual variation of telomere length. However, it is potentially useful 
in monitoring progression of CHF, since it has been suggested that a gradual 
inverse relationship exists between telomere length and severity of disease in CHF 
patients.3 Before this can be applied in clinical practice, this gradual effect must be 
investigated more extensively.  
 
To conclude, in this thesis we have confirmed the inverse association between 
telomere length and CHF and associated factors. We have established factors 
associated with telomere length in time. Also, we have ruled out one possible 
mechanism underlying the role of telomere length in CHF. Despite our efforts, the 
question on the nature of the association between CHF and telomere length still 
remains. To elucidate the precise role of telomere length in the pathophysiology of 
CHF and its potential role in therapeutic or diagnostic strategies, more mechanistical 
as well as longitudinal observational studies are needed. 
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Chronisch hartfalen (CHF) is een aandoening die wereldwijd miljoenen patiënten 
treft. Hoewel veelvuldig onderzoek tot de ontdekking van verschillende 
risicofactoren voor CHF heeft geleid, zijn de precieze mechanismen van het ontstaan 
en de progressie van CHF nog niet geheel duidelijk.
 Ongeveer een decennium geleden werd voor het eerst geopperd dat 
telomeerlengte mogelijk een rol speelt in de pathofysiologie van CHF. Telomeren 
zijn de uiteinden van chromosomen. Door de speciale structuur waarin telomeren 
“opgevouwen” zijn, beschermen ze het uiteinde van het DNA waaruit chromosomen 
zijn opgebouwd. Ernstige telomeerverkorting kan leiden tot celdisfunctie of zelfs 
apoptose, geprogrammeerde celdood, wat schadelijk voor het organisme kan zijn. 
Dit beschermingsmechanisme is echter niet feilloos en er vindt tijdens het leven 
door verschillende mechanismen toch verkorting plaats van telomeren. 
 Uit onderzoeken is gebleken dat patiënten met CHF kortere telomeren hebben 
dan hun gezonde leeftijdsgenoten. Korte telomeerlengte lijkt dus samen te hangen 
met CHF. Belangrijk is de vraag of telomeerlengte verkorting vooraf ging aan het 
ontstaan van CHF of dat het het gevolg is van CHF, of zelfs helemaal niets met 
elkaar te maken hebben maar slechts “toevallig” tegelijkertijd worden geobserveerd 
in CHF patiënten. Indien telomeerverkorting vooraf gaat aan CHF, betekent dit dat 
telomeerlengte mogelijk een factor is die bijdraagt aan het ontstaan van CHF en 
daarbij mogelijk ook een ingang is voor een nieuwe behandeling.
 Hoewel verschillende onderzoekers een associatie tussen korte telomeerlengte 
en CHF hebben geconstateerd, is er weinig gespeculeerd over mogelijke verklaringen 
voor deze associatie en is er nog minder wetenschappelijk bewijs dat deze mogelijke 
verklaringen ondersteunt. In dit proefschrift hebben wij de associatie tussen korte 
telomeerlengte en CHF onderzocht.
Het eerste gedeelte van dit proefschrift richt zich op de klinische associaties tussen 
telomeerlengte en CHF. 
 Hoofdstuk 1 geeft een overzicht van de literatuur over de associatie 
tussen telomeerlengte en CHF of risicofactoren voor CHF. Korte telomeerlengte 
is herhaaldelijk in verband gebracht met atherosclerose (in de volksmond 
“vaatverkalking”) en hartinfarcten. Daarnaast is telomeerlengte ook geassocieerd 
met klassieke risicofactoren voor hart- en vaatziekten, zoals hoge bloeddruk, 
suikerziekte en roken.
 Hoofdstukken 2 en 3 laten zien dat telomeerlengte ook geassocieerd is 
met nevenziekten die vaak optreden bij CHF patiënten. Hoofdstuk 2 beschrijft 
de associatie tussen korte telomeerlengte en het voorkomen van anemie 
(bloedarmoede), wat ook een vaak voorkomende nevenziekte van CHF is. De vraag 
rijst of het hier gaat om een causaal verband. Helaas laat de opzet van dit onderzoek 
niet toe dat we op basis van dit onderzoek hier conclusies over trekken. Andere 
onderzoeken hebben echter laten zien dat telomeerlengte van witte bloedcellen sterk 
overeenkomt met telomeerlengte van beenmergcellen en dat korte telomeerlengte 
in het beenmerg – waar rode bloedcellen worden aangemaakt – de bloedvormende 
capaciteit van het beenmerg vermindert. Dit is natuurlijk indirect bewijs, maar het 
wekt wel de suggestie dat bloedarmoede in CHF patiënten zou kunnen voortkomen 
uit verminderde functie van het beenmerg met korte telomeren. In hoofdstuk 3 is 
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te lezen dat er een omgekeerde relatie bestaat tussen telomeerlengte en geschatte 
nierfunctie in CHF patiënten. Er zijn verschillende denkbare verklaringen hiervoor. 
Slechte nierfunctie veroorzaakt verhoogde oxidatieve stress. Oxidatieve stress is 
een bekende factor die telomeerlengteverkorting veroorzaakt. In dit scenario zou 
telomeerlengte dus een marker zijn voor schade aan het lichaam dat veroorzaakt 
wordt door nierfalen. In een ander scenario zou telomeerlengte ook een causale factor 
kunnen zijn voor het ontstaan van nierfalen in CHF patiënten, als we ervan uit gaan 
dat telomeerlengte van witte bloedcellen (die wij hebben gemeten) een afspiegeling 
is van telomeerlengte van andere lichaamscellen. Cellen met korte telomeren 
zijn kwetsbaarder voor schadelijke externe factoren. Als de nierencellen korte 
telomeren hebben, zouden de nieren kwetsbaarder zijn en sneller last functieverlies 
kunnen krijgen. Hoofdstuk 4 beschrijft een groot, longitudinaal onderzoek naar de 
associatie tussen telomeerlengte en cardiovasculaire risicofactoren in een populatie 
van ongeveer 8000 mensen met albuminurie (eiwit in de urine). Dit is het eerste 
klinische onderzoek van deze omvang met telomeerlengte gemeten op meerdere 
tijdstippen. We hebben laten zien dat snelheid van telomeerverkorting geassocieerd 
is met bekende risicofactoren voor hart- en vaatziekten, zoals roken, overgewicht 
en hoog bloedsuikergehalte. Daarentegen was een hoog bloed-HDL gehalte (het 
“goede cholesterol”) geassocieerd met langzamere telomeerverkorting. Op basis 
van deze onderzoeksresultaten zou je kunnen speculeren over de invloed van 
leefstijl en –gewoontes op telomeerlengteverkorting. Door een gezondere leefstijl 
aan te houden kan wellicht telomeerlengteverkorting worden vertraagd.
Het tweede gedeelte van dit proefschrift richt zich op de mogelijke mechanismen 
die ten grondslag liggen aan de geobserveerde klinische associaties tussen korte 
telomeerlengte en CHF.
 In hoofdstuk 5 wordt het telomerase-deficiënte muismodel beschreven als 
model voor cardiovasculair onderzoek. Telomerase-deficiënte muizen werder 
oorspronkelijk gebruikt voor onderzoek naar kanker, omdat telomerase-activiteit 
vaak een rol speelt bij het ontstaan van kanker. Dit muismodel kan echter ook 
uitstekend worden gebruikt om eventuele onderliggende mechanismen van 
de relatie tussen telomeerlengte en hart- en vaatziekten te onderzoeken. Om 
mechanistisch onderzoek te doen zijn niet-menselijke onderzoeksmodellen 
onontbeerlijk omdat vele omgevingsfactoren (zoals bijvoorbeeld woonomgeving 
en dieet) controleerbaar moeten zijn en bovendien de genetische achtergrond van 
de onderzochte organismen nagenoeg gelijk moet zijn. Het is niet moeilijk voor te 
stellen dat dit bij mensen praktisch onhaalbaar is en we daarom diermodellen nodig 
hebben.
 In hoofdstuk 6 hebben we telomeerlengte onderzocht in leukocyten en 
circulerende cardiovasculaire voorlopercellen (cellen die schade aan het hart- en 
vaatstelstel zouden kunnen reparere) en vroegen ons af of deze cellen een kortere 
telomeerlengte hebben bij CHF patiënten dan bij gezonde controles. We hebben 
bevestigd dat dit het geval is in leukocyten. Daarnaast hebben we laten zien dat dit 
zelfs het geval is bij de (nog) gezonde kinderen van beide groepen. Het is bekend 
dat kinderen van ouders met hart- en vaatziekten een hoger risico hebben op het 
ontwikkelen van hart- en vaatziekten. Dat telomeren al korter zijn bij de gezonde 
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kinderen van CHF patiënten vergeleken met gezonde kinderen van gezonde 
patiënten zou impliceren dat telomeerlengteverkorting vooraf gaat aan het ontstaan 
van CHF. Daarnaast hebben we laten zien dat telomeerlengte in de voorlopercellen 
niet verschillend is in de groepen, wat een rol voor deze cellen in de relatie tussen 
telomeren en CHF erg klein maakt. 
 Tenslotte hebben we in hoofdstuk 7 de veroudering van hart en vaten en de rol 
van telomeren in dit verouderingsproces en hart- en vaatziekten beschreven.
Toekomstperspectieven.
De centrale vraag met betrekking tot de associatie tussen telomeren en CHF blijft 
of het een causaal verband betreft of niet. De meeste wetenschappelijke bewijzen 
voor deze associatie zijn voortgekomen uit observationele klinische onderzoeken. 
Deze onderzoeken hebben voornamelijk naar telomeerlengte in witte bloedcellen 
bekeken, omdat deze gemakkelijk te verkrijgen zijn met een “bloedprik”.1-7 Het is 
echter nog niet onomstotelijk vastgesteld dat telomeerlengte in witte bloedcellen 
telomeerlengte in de rest van het lichaam en met name het hart weerspiegelt. Dit is 
belangrijk om te weten, omdat we dan weten of de link tussen korte telomeerlengte 
en CHF mogelijk in het hartweefsel zit of dat we het moeten zoeken in 
overkoepelende systemische factoren die invloed hebben op zowel telomeerlengte 
als hartfunctie. Hartweefsel van mensen verzamelen is echter zeer moeilijk en het is 
dus de vraag wanneer er overtuigend bewijs uit grootschalige onderzoeken komt 
dat telomeerlengte in het hart wel of niet wordt weerspiegeld door die van witte 
bloedcellen.
 Zoals eerder gezegd kan het telomerase-deficiënte muismodel uitkomst 
bieden. Het zou interessant zijn om te onderzoeken of late generaties van deze 
muizen – die korte telomeren hebben – sneller of ernstiger hartfalen krijgen dan 
gezonden wild type muizen na een hartinfarct en wat het effect van medicatie tegen 
hartfalen is in beide groepen. 
 Een andere vraag is wat de klinische toepasbaarheid van telomeerlengte 
is. Dit wordt in grote mate bepaald door de aard van de relatie tussen 
telomeerlengte en CHF (causaal of niet). Als deze relatie causaal blijkt te zijn, 
zouden telomeerstabiliserende of zelfs –verlengende strategieën denkbaar kunnen 
zijn. Statines zouden bijvoorbeeld telomeerlengte stabiliseren.8 In theorie is het 
ook mogelijk om cellen met kunstmatig verlengde telomeren te transplanteren 
om het verzwakte hart te ondersteunen of herstellen. Hier komen echter serieuze 
problemen bij kijken. Ten eerste blijkt het in de praktijk erg lastig om de “losse” 
cellen verweven te krijgen in hartweefsel.9 Daarnaast lijken deze cellen verminderd 
levensvatbaar. Transplantatie van deze cellen klinkt wellicht veelbelovend, maar 
er moeten nog veel obstakels in de praktijk worden overwonnen en de effectiviteit 
moet daarna nog worden aangetoond.
 Telomeerlengte zou ook kunnen dienen als marker van CHF. Om CHF te 
diagnostiseren zou het waarschijnlijk niet toepasbaar zijn, omdat telomeerlengte erg 
kan verschillen tussen verschillende mensen. Mogelijk kan het wel ingezet worden 
om verslechtering van CHF te monitoren. Patiënten met ernstig CHF lijken namelijk 
kortere telomeren te hebben dan patiënten met minder ernstig CHF.3 Dit zou eerst 




Concluderend hebben we in dit proefschrift bevestigd dat er een omgekeerde 
relatie bestaat tussen telomeerlengte en CHF en CHF-gerelateerde factoren. Ook 
hebben we laten zien dat deze relatie in de tijd blijft bestaan. Daarnaast hebben we 
aangetoond dat de cardiovasculaire voorlopercellen geen rol spelen in het eventuele 
onderliggende mechanisme van de relatie tussen telomeerlengte en CHF. Ondanks 
onze pogingen deze relatie grondig te onderzoeken, blijft de vraag bestaan of het 
gaat om een causaal verband of niet. Om de precieze rol van telomeren in CHF en 
eventuele klinische toepasbaarheid van deze kennis te begrijpen, is er zowel meer 
mechanistisch als longitudinaal onderzoek nodig.
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hebben bijgedragen aan mijn positieve ervaringen en de totstandkoming van 
dit proefschrift.
Allereerst mijn promotores en copromotores.
Prof. dr. D.J. van Veldhuisen, beste Dirk Jan. Vanaf het allereerste begin van 
mijn tijd als onderzoeker bij de afdeling Cardiologie maakte jij duidelijk dat 
ik je steun had. Je gaf mij altijd het gevoel dat je in mij geloofde en dat was een 
zeer motiverende en bemoedigende gedachte. Je creativiteit en enthousiasme 
vormden een grote bijdrage aan de totstandkoming van dit proefschrift. Heel 
erg bedankt hiervoor.
Prof. dr. W.H. van Gilst, beste Wiek. Jouw deur stond altijd open voor…
eigenlijk alles wat een promovendus tijdens een promotietraject kon 
tegenkomen; de moeilijke momenten maar ook de momenten van blijdschap 
en plezier. Je was altijd zeer benaderbaar en dat maakt jou een grote 
steun voor vele promovendi en zo ook voor mij. Niet alleen was je er om 
wetenschappelijke ideeën en resultaten te bespreken, ook stond je altijd klaar 
om iemand een hart onder de riem te steken of advies te geven. Mijn grote 
dank hiervoor!
Dr. P. van der Harst, beste Pim. Wij leerden elkaar inmiddels bijna zeven jaar 
geleden kennen, ik als student en jij als onderzoeker op de afdeling Klinische 
Farmacologie. Toen al waardeerde ik je om je passie voor de wetenschap en 
inspirerende inzichten en dat is niet veranderd. Toen ik begreep dat jij mijn 
dagelijkse begeleider zou worden tijdens dit promotie-traject wist ik zeker: 
het komt allemaal goed. Mijn oprechte dank voor jouw grote inzet voor mij 
en dit proefschrift.
Dr. R.A. de Boer, beste Rudolf. Dank je wel voor het meedenken en begeleiden 
tijdens mijn onderzoeksperiode. Jouw luchtige aanpak waren op sommige 
momenten onmisbaar. Daarnaast maakte de jou zo kenmerkende humor 
werken met jou erg aangenaam.
I would also like to thank the members of the reading committee for carefully 
reading this thesis and their valuable comments: Prof. dr. A.C. van Rossum, 
Prof. dr. N.J. Samani, and Prof. dr. M.P. van den Berg.
Een promotietijd zou geen promotietijd zijn zonder de gezelligheid. Allereerst 
gaat mijn dank uit naar mijn “partner in crime” Jardi. Beste Jardi, we hebben 
het er vaak over gehad hoe verbazingwekkend goed zulke tegenpolen als 
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jij en ik door één deur konden (en volgens mij waren wij niet de enigen die 
zich daarover verbaasden). Zoals we zelf al redeneerden: onze verschillen 
zitten voornamelijk aan de oppervlakte. Over de belangrijke dingen in het 
leven dachten we veelal hetzelfde en dat schepte een hechte band. Als Telo-
tweeling banjerden we gezamenlijk door de gangen en het labwerk werd 
samen met jou een stuk lichter. Ook zullen onze gesprekken (of waren het 
vooral mijn monologen?) me lang bijblijven. Dank dat ik de afgelopen jaren 
met je heb mogen lachen, kletsen, filosoferen en discussiëren, op het werk en 
daarbuiten. Promoveren zou lang niet zo leuk zijn geweest zonder jou! Ik ben 
blij dat we dit allemaal (behalve de halve nachten doorhalen op het lab) nog 
geregeld doen! Daarnaast wil ik mijn kamergenoten Anne en Willem-Peter 
bedanken voor de gezelligheid en fantastische sfeer op onze kamer. Ik vind 
het super dat we elkaar nog geregeld zien en spreken en hoop dat we elkaar 
in de toekomst vaak zullen blijven opzoeken!
Beste (oud) Greenhouse bewoners in willekeurige volgorde: Renée, Pieter-
Jan, Kevin, Marcelle, Hessel, Bart, Lennaert, Caroline, Lieuwe, Pieter, Frank, 
Ali, Daan, Wouter, Nicolas, Jasper, Arjen, Sheba, Marthe, Mirjam, Rob, Ismaël, 
Ymkje, Chris, Matthijs, Sandra, Jan-Pieter, Marieke, Karim, Vincent, Suzan, 
Youlan, bedankt voor de vele cola-rondjes en Feithuis borrels! Het eerste 
Greenhouse weekend was onvergetelijk!
Verder de collega’s van de Cardio Research: Carolien, Greetje, Peter, Margriet, 
Geert, Trienke, Karin en Carlien. Dank jullie wel voor de altijd prettige 
samenwerking! Greetje en Margriet, dank jullie wel voor jullie betrokkenheid. 
Carolien, jouw gevoel voor humor, relativeringsvermogen en de gesprekken 
die wij voerden onder het genot van (te) sterke koffie en koekjes heb ik 
altijd enorm gewaardeerd! De recente gebeurtenissen lieten mij des te meer 
beseffen hoezeer ik jou waardeer. 
 Ook wil de mensen van de COACH groep bedanken voor de fijne 
samenwerking, in het bijzonder Tiny, Martje, Ivonne en Marie-Louise.
Uiteraard gaat ook mijn dank uit naar mijn collega’s van “de vijfde en de 
zesde” en andere mensen die hebben bijgedragen aan het lab-gedeelte van 
het werk: Irma, Hisko, Michael, Maaike, Femke, Irene, Carla, Herman, Hasan, 
Silke, MeiMei, Marjan, Leonie, Bo, Mariusz, Anne-Margreet, Reinout, LiLi, 
Wardit, Linda, Megan, Bianca, Janny, Bibiche, Jacko, Henk Moorlag, Pauline 
Snijder en uit mijn wetenschappelijke stage-tijd Willemijn.
 Lieve Irma, wat heb ik genoten van jouw stralende aanwezigheid! Jouw 
gevoel voor humor en onzelfzuchtigheid zijn uniek. Ik denk met veel plezier 
terug aan onze verkenningstochten door Barcelona, onze paranimf-taken 
voor Hisko, zanglessen, etentjes, shop-avonturen, elkaar uit de lappenmand 
trekken en alle andere ontelbare gezellige en waardevolle momenten. Ik vind 
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Dankwoord
het heel erg leuk dat we deze activiteiten gewoon voortzetten. En Marc: dank 
je wel voor je creatieve en enthousiaste hulp bij het maken van de omslag. 
    Hisko, onze rots in de branding op de afdeling! Jij stond als stabiele 
factor altijd klaar voor andere AIO’s, of het nou om hulp bij lab-technieken of 
een luisterend oor ging. Daarnaast was je altijd te porren voor welke gezellige 
gelegenheid dan ook.
    Germaine, Annet en Martin, jullie hulp bij de experimenten werd zeer 
gewaardeerd. Germaine, zonder jou zou de telomeerPCR niet op zo’n snelle 
en gedegen manier van de grond zijn gekomen. Ik bewonder je nog steeds om 
je moedige stap naar de studie Geneeskunde. Het lijkt me niet gemakkelijk, 
maar ik voorzie voor jou geen probleem. Jouw expertise, nauwgezetheid 
en vastberadenheid om problemen tot de kern te doorgronden zullen je 
hierbij vast en zeker helpen. Daarnaast werd er tijdens het werken met jou 
ook heel wat afgelachen, iets wat we zeker vaker samen gaan doen! Annet, 
mijn nanodrop-maatje... Die vier dagen staan me nog bijzonder goed bij. Met 
niemand anders had ik op zo’n manier kunnen knallen om in bijzonder korte 
tijd van 17.796 samples de DNA-concentratie te meten. Inge, zonder jouw 
hulp had het laatste experiment er vast heel anders uitgezien. Dank voor je 
inzet! Maaike en Femke, dank voor de gezellige thee-momentjes! Michael, 
ik kijk uit naar onze volgende fietstocht. Inmiddels zal ik je zeker kunnen 
bijhouden (als we tenminste geen leeuwen tegenkomen). Succes met de rest 
van je onderzoek! 
Ik heb het al vaak gezegd, maar bij deze nog een keer: Alma, wat zouden we 
toch zonder je moeten? Je bent echt, écht onmisbaar in de laatste fase van het 
promotietraject. Heel veel dank voor al je hulp! Audrey, ook bedankt voor je 
hulp!
Lieve (nog niet genoemde) vrienden en vriendinnen, wat ben ik blij met jullie! 
Lieve Renske, dank je wel voor je vriendschap de afgelopen jaren! Jij werpt 
altijd nieuw licht op zaken en ik hoop dat ik nog heeeeeeel lang je van je 
vriendschap mag genieten, je om advies mag komen vragen en vooral heel 
veel lol met je mag beleven. En bedankt dat je op de moeilijke momenten 
altijd naast me staat. Rosie, ik ben blij dat we elkaar beter hebben leren 
kennen en ik vind het altijd supergezellig met je. Heel erg leuk dat we elkaar 
zo vaak zien nu ik in Amsterdam woon. Anton, gek genoeg kunnen we ons 
geen van beiden herinneren hoe onze vriendschap precies begon, wat maar 
onderstreept dat het op een heel natuurlijke manier tot stand is gekomen. 
Bedankt voor je steun tijdens de moeilijke momenten en ik hoop dat je weet 
dat ik je nuchtere kijk op de wereld en de gezellige momenten met je heel erg 
waardeer. Kuikentje (ben ik inmiddels echt de enige die jou nog zo noemt?), 
dank je wel voor je vriendschap, steun, nuchterheid en alle gezelligheid en ik 
kijk uit naar ons volgende rendez-vous!!
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Mijn paranimfen:
Lieve Janneke, je kent me als geen ander en staat altijd klaar met praktisch 
advies en bemoedigende woorden als het nodig is. Dank je wel hiervoor! En 
natuurlijk ook voor alle gezellige, soms emotionele en moeilijke, maar vooral 
heel erg leuke momenten die we hebben gedeeld. Ik heb erg genoten van de 
tijd dat we huisgenoten waren en mis nog steeds onze ochtendrituelen van 
toen! En je weet: als we tachtig zijn zullen we in het bejaardentehuis stug blijven 
doorlopen op ons hippe schoeisel. Ik hoop dat ik nog vele jaren lief en leed met 
jou mag delen!
Lieve Willy, vanaf het allereerste begin van mijn wetenschappelijke carrière 
stond jij al (letterlijk) naast me. Ik heb zo veel van je geleerd, over onderzoeks- 
en niet-onderzoeks-gerelateerde zaken. Ik waardeer en bewonder jouw 
oprechtheid en openheid enorm en het is heel fijn om te weten dat ik altijd met 
alles bij je terecht kan. Ik ben heel erg blij met jou als vriendin en hoop nog vaak 
met jou en Felix leuke dingen te ondernemen!
Tenslotte, lieve familie, jullie mogen natuurlijk niet ontbreken in dit dankwoord. 
Amy, hoewel we geregeld van mening verschillen, zullen we altijd op elkaar 
terug kunnen vallen. Mam, je hebt je altijd enorm ingezet om mij een onbezorgde 
jeugd en een stevige basis te bezorgen, dat is je ruimschoots gelukt. Ik ben je 
dankbaar dat je me hebt meegegeven altijd het beste uit mezelf proberen te 
halen. Pap, je kon vandaag niet meer meemaken, maar in gedachten ben je bij 
me. Dank je wel voor alles wat je als vader voor mij hebt gedaan. 
